Explanation
This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
miRNA-gene regulations
| Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | hsa-let-7a-5p | AIFM1 | -1.37 | 0 | 0.7 | 0 | TargetScan; miRNATAP | -0.11 | 0.00018 | NA | |
| 2 | hsa-let-7b-5p | AIFM1 | -1.62 | 0 | 0.7 | 0 | miRNATAP | -0.12 | 0 | NA | |
| 3 | hsa-let-7a-5p | AKT2 | -1.37 | 0 | 0.16 | 0.1135 | TargetScan | -0.12 | 0 | NA | |
| 4 | hsa-miR-29a-3p | AKT2 | 0.1 | 0.5732 | 0.16 | 0.1135 | MirTarget | -0.1 | 4.0E-5 | 24076586 | Furthermore a feed-back loop comprising of c-Myc miR-29 family and Akt2 were found in myeloid leukemogenesis |
| 5 | hsa-miR-106b-5p | AKT3 | 1.47 | 0 | -1.44 | 0 | miRNATAP | -0.16 | 0.00426 | NA | |
| 6 | hsa-miR-107 | AKT3 | 0.66 | 0 | -1.44 | 0 | PITA; miRanda | -0.26 | 0.0031 | NA | |
| 7 | hsa-miR-146b-5p | AKT3 | 1.09 | 1.0E-5 | -1.44 | 0 | miRNAWalker2 validate | -0.15 | 0.00189 | NA | |
| 8 | hsa-miR-15a-5p | AKT3 | 1.63 | 0 | -1.44 | 0 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.41 | 0 | NA | |
| 9 | hsa-miR-16-5p | AKT3 | 0.75 | 0 | -1.44 | 0 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.27 | 0.0001 | NA | |
| 10 | hsa-miR-17-5p | AKT3 | 2.07 | 0 | -1.44 | 0 | TargetScan; miRNATAP | -0.22 | 0 | NA | |
| 11 | hsa-miR-181a-5p | AKT3 | -0.38 | 0.05621 | -1.44 | 0 | miRNATAP | -0.23 | 9.0E-5 | NA | |
| 12 | hsa-miR-181b-5p | AKT3 | 0.67 | 0.00024 | -1.44 | 0 | miRNATAP | -0.37 | 0 | NA | |
| 13 | hsa-miR-20a-5p | AKT3 | 2.65 | 0 | -1.44 | 0 | miRNATAP | -0.24 | 0 | NA | |
| 14 | hsa-miR-22-3p | AKT3 | 1.43 | 0 | -1.44 | 0 | miRNATAP | -0.26 | 0.00109 | NA | |
| 15 | hsa-miR-29b-2-5p | AKT3 | 0.35 | 0.19484 | -1.44 | 0 | mirMAP | -0.18 | 2.0E-5 | NA | |
| 16 | hsa-miR-29b-3p | AKT3 | 3.11 | 0 | -1.44 | 0 | miRNATAP | -0.27 | 0 | 26512921 | MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3 |
| 17 | hsa-miR-3065-5p | AKT3 | 0.65 | 0.09995 | -1.44 | 0 | mirMAP | -0.18 | 0 | NA | |
| 18 | hsa-miR-362-5p | AKT3 | 0.66 | 0.02433 | -1.44 | 0 | PITA; TargetScan; miRNATAP | -0.23 | 0 | NA | |
| 19 | hsa-miR-542-3p | AKT3 | 1.62 | 0 | -1.44 | 0 | miRanda | -0.19 | 1.0E-5 | NA | |
| 20 | hsa-miR-93-5p | AKT3 | 1.51 | 0 | -1.44 | 0 | miRNATAP | -0.25 | 0 | NA | |
| 21 | hsa-miR-23a-3p | APAF1 | 0.11 | 0.39309 | 0.05 | 0.6283 | miRNATAP | -0.13 | 0.00069 | 24992592; 24249161 | Luciferase assay was performed to verify a putative target site of miR-23a in the 3'-UTR of apoptosis protease activating factor 1 APAF1 mRNA; The expression levels of miR-23a and APAF1 in CRC cell lines SW480 and SW620 and clinical samples were assessed using reverse transcription-quantitative real-time PCR RT-qPCR and Western blot; Moreover miR-23a up-regulation was coupled with APAF1 down-regulation in CRC tissue samples;We found that the expression of miR-23a was increased and the level of apoptosis-activating factor-1 APAF-1 was decreased in 5-FU-treated colon cancer cells compared to untreated cells; APAF-1 as a target gene of miR-23a was identified and miR-23a antisense-induced increase in the activation of caspase-9 was observed |
| 22 | hsa-miR-23b-3p | APAF1 | -0.07 | 0.62059 | 0.05 | 0.6283 | miRNATAP | -0.11 | 0.00216 | NA | |
| 23 | hsa-miR-27a-3p | APAF1 | 0.43 | 0.00737 | 0.05 | 0.6283 | miRNATAP | -0.16 | 0 | NA | |
| 24 | hsa-miR-27b-3p | APAF1 | 0.24 | 0.12264 | 0.05 | 0.6283 | miRNATAP | -0.17 | 0 | NA | |
| 25 | hsa-miR-664a-3p | APAF1 | 0.44 | 0.02142 | 0.05 | 0.6283 | mirMAP | -0.11 | 2.0E-5 | NA | |
| 26 | hsa-miR-15a-5p | BCL2 | 1.63 | 0 | -0.49 | 0.06421 | miRNAWalker2 validate; miRTarBase | -0.19 | 0.00401 | 26915294; 25594541; 18931683; 25623762; 22335947 | As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;MicroRNAs miRNAs are noncoding small RNAs that repress protein translation by targeting specific messenger RNAs miR-15a and miR-16-1 act as putative tumor suppressors by targeting the oncogene BCL2;miR 15a and miR 16 modulate drug resistance by targeting bcl 2 in human colon cancer cells; To investigate the reversal effect of targeted modulation of bcl-2 expression by miR-15a and miR-16 on drug resistance of human colon cancer cells;The expression of MiR-15a was significantly inhibited by Bcl-2 P < 0.05 |
| 27 | hsa-miR-21-5p | BCL2 | 4.38 | 0 | -0.49 | 0.06421 | miRNAWalker2 validate; miRTarBase | -0.2 | 1.0E-5 | 22964582; 21468550; 25994220; 25381586; 26555418; 23359184; 21376256 | Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;BCL-2 up-regulation could be achieved by miR-21 overexpression which prevented T24 cells from apoptosis induced by doxorubicin; Furthermore the miR-21 induced BCL-2 up-regulation could be cancelled by the PI3K inhibitor LY294002;Meanwhile miR-21 loss reduced STAT3 and Bcl-2 activation causing an increase in the apoptosis of tumour cells in CAC mice;Changes in the sensitivity of osteosarcoma cells to CDDP were examined after transfection with miR-21 mimics or anti-miR-21 or bcl-2 siRNA in combination with CDDP;The expression of Bax Bcl-2 and miR-21 in parental and paclitaxel-resistant cells was detected by RT-PCR and Western blotting;Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR 21 regulation of BCL 2 expression; We also used Western blot to measure BCL-2 protein levels after down-regulation of miR-21 expression; Besides down-regulation of miR-21 expression can inhibit BCL-2 expression in PANC-1 CFPAC-1 and MIA Paca-2 cells; Over-expression of miR-21 expression can reverse down-regulation of BCL-2 expression and apoptosis induced by resveratrol; In this study we demonstrated that the effect of resveratrol on apoptosis is due to inhibiting miR-21 regulation of BCL-2 expression;Bcl 2 upregulation induced by miR 21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa 2 pancreatic cancer cells; However the roles and mechanisms of miRNA miR-21 in regulation of Bcl-2 in pancreatic cancer remain to be elucidated; Then luciferase activity was observed after miR-21 mimics and pRL-TK plasmids containing wild-type and mutant 3'UTRs of Bcl-2 mRNA were co-transfected; Cells transfected with miR-21 inhibitor revealed an opposite trend. There was a significant increase in luciferase activity in the cells transfected with the wild-type pRL-TK plasmid in contrast to those transfected with the mutant one indicating that miR-21 promotes Bcl-2 expression by binding directly to the 3'UTR of Bcl-2 mRNA; Upregulation of Bcl-2 directly induced by miR-21 is associated with apoptosis chemoresistance and proliferation of MIA PaCa-2 pancreatic cancer cells |
| 28 | hsa-miR-224-5p | BCL2 | 1.92 | 0 | -0.49 | 0.06421 | mirMAP | -0.14 | 0 | 24796455 | In addition the expressions of Bcl2 mRNA and protein were 1.05 ± 0.04 and 0.21 ± 0.03 in the miR-224 ASO group significantly lower than that in the control group 4.87 ± 0.96 and 0.88 ± 0.09 P < 0.01 |
| 29 | hsa-miR-24-2-5p | BCL2 | 1.44 | 0 | -0.49 | 0.06421 | miRNAWalker2 validate; miRTarBase | -0.16 | 0.00352 | NA | |
| 30 | hsa-miR-29a-5p | BCL2 | 1.9 | 0 | -0.49 | 0.06421 | mirMAP | -0.24 | 0 | 20041405 | Subsequent investigation characterized two antiapoptotic molecules Bcl-2 and Mcl-1 as direct targets of miR-29; Furthermore silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29 whereas overexpression of these proteins attenuated the effect of miR-29 |
| 31 | hsa-miR-3065-5p | BCL2 | 0.65 | 0.09995 | -0.49 | 0.06421 | mirMAP | -0.12 | 0.00023 | NA | |
| 32 | hsa-miR-34a-5p | BCL2 | 1.41 | 0 | -0.49 | 0.06421 | miRNAWalker2 validate; miRTarBase | -0.19 | 0.00135 | 22964582; 24565525; 23155233; 24444609; 20687223; 22623155; 24988056; 18803879; 19714243; 25053345; 20433755; 21399894; 23862748 | Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;In vitro and in vivo experiments showed that miR-34a and DOX can be efficiently encapsulated into HA-CS NPs and delivered into tumor cells or tumor tissues and enhance anti-tumor effects of DOX by suppressing the expression of non-pump resistance and anti-apoptosis proto-oncogene Bcl-2;The miR-34a expression levels in cells after irradiation at 30 and 60 Gy were 0.17- and 18.7-times the BCL2 and caspase-9 expression levels respectively;Functional analyses further indicate that restoration of miR-34a inhibits B cell lymphoma-2 Bcl-2 protein expression to withdraw the survival advantage of these resistant NSCLC cells;Thus in PC3PR cells reduced expression of miR-34a confers paclitaxel resistance via up-regulating SIRT1 and Bcl2 expression; MiR-34a and its downstream targets SIRT1 and Bcl2 play important roles in the development of paclitaxel resistance all of which can be useful biomarkers and promising therapeutic targets for the drug resistance in hormone-refractory prostate cancer;MiR 34a inhibits proliferation and migration of breast cancer through down regulation of Bcl 2 and SIRT1; In this study we aimed to determine the effect of miR-34a on the growth of breast cancer and to investigate whether its effect is achieved by targeting Bcl-2 and SIRT1; Bcl-2 and SIRT1 as the targets of miR-34a were found to be in reverse correlation with ectopic expression of miR-34a;Target analysis indicated that micro RNA miR-34a directly regulates Bcl-2 and miR-34a overexpression decreased Bcl-2 protein level in gastric cancer cells; We also found that luteolin upregulates miR-34a expression and downregulates Bcl-2 expression; Based on these results we can draw the conclusion that luteolin partly decreases Bcl-2 expression through upregulating miR-34a expression;miR-34 targets Notch HMGA2 and Bcl-2 genes involved in the self-renewal and survival of cancer stem cells; Human gastric cancer cells were transfected with miR-34 mimics or infected with the lentiviral miR-34-MIF expression system and validated by miR-34 reporter assay using Bcl-2 3'UTR reporter; Human gastric cancer Kato III cells with miR-34 restoration reduced the expression of target genes Bcl-2 Notch and HMGA2; Bcl-2 3'UTR reporter assay showed that the transfected miR-34s were functional and confirmed that Bcl-2 is a direct target of miR-34; The mechanism of miR-34-mediated suppression of self-renewal appears to be related to the direct modulation of downstream targets Bcl-2 Notch and HMGA2 indicating that miR-34 may be involved in gastric cancer stem cell self-renewal/differentiation decision-making;Among the target proteins regulated by miR-34 are Notch pathway proteins and Bcl-2 suggesting the possibility of a role for miR-34 in the maintenance and survival of cancer stem cells; Our data support the view that miR-34 may be involved in pancreatic cancer stem cell self-renewal potentially via the direct modulation of downstream targets Bcl-2 and Notch implying that miR-34 may play an important role in pancreatic cancer stem cell self-renewal and/or cell fate determination;Manipulating miR-34a in prostate cancer cells confirms that this miRNA regulates BCL-2 and may in part regulate response to docetaxel;For instance miR-34a up-regulation corresponded with a down-regulation of BCL2 protein; Treating Par-4-overexpressing HT29 cells with a miR-34a antagomir functionally reversed both BCL2 down-regulation and apoptosis by 5-FU;Quantitative PCR and western analysis confirmed decreased expression of two genes BCL-2 and CCND1 in docetaxel-resistant cells which are both targeted by miR-34a;MicroRNA 34a targets Bcl 2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment; HCC tissues with lower miR-34a expression displayed higher expression of Bcl-2 protein than those with high expression of miR-34a; therefore an inverse correlation is evident between the miR-34a level and Bcl-2 expression; Bioinformatics and luciferase reporter assays revealed that miR-34a binds the 3'-UTR of the Bcl-2 mRNA and represses its translation; Western blotting analysis and qRT-PCR confirmed that Bcl-2 is inhibited by miR-34a overexpression; Functional analyses indicated that the restoration of miR-34a reduced cell viability promoted cell apoptosis and potentiated sorafenib-induced apoptosis and toxicity in HCC cell lines by inhibiting Bcl-2 expression |
| 33 | hsa-miR-450b-5p | BCL2 | 1.69 | 0 | -0.49 | 0.06421 | mirMAP | -0.2 | 0 | NA | |
| 34 | hsa-miR-452-5p | BCL2 | 0.64 | 0.04582 | -0.49 | 0.06421 | mirMAP | -0.12 | 0.00113 | NA | |
| 35 | hsa-miR-542-3p | BCL2 | 1.62 | 0 | -0.49 | 0.06421 | mirMAP | -0.19 | 3.0E-5 | NA | |
| 36 | hsa-miR-590-5p | BCL2 | 2.07 | 0 | -0.49 | 0.06421 | miRanda | -0.18 | 0.00054 | NA | |
| 37 | hsa-miR-96-5p | BCL2 | 3.04 | 0 | -0.49 | 0.06421 | miRNAWalker2 validate; TargetScan | -0.14 | 0.00193 | NA | |
| 38 | hsa-miR-500a-5p | BIRC2 | 0.65 | 0.01047 | -0.06 | 0.62026 | MirTarget | -0.11 | 0 | NA | |
| 39 | hsa-miR-24-1-5p | BIRC3 | 0.86 | 0.00011 | 0.13 | 0.67648 | MirTarget | -0.21 | 0.00165 | NA | |
| 40 | hsa-miR-375 | BIRC3 | 0.62 | 0.1492 | 0.13 | 0.67648 | miRNAWalker2 validate | -0.2 | 0 | 23726271 | Taken together these data suggest that miR-375 sensitizes TNF-α-induced apoptosis and the reduction in the expression of the apoptosis inhibitory proteins cFLIP-L and cIAP2 plays an important role in this sensitization |
| 41 | hsa-miR-16-2-3p | CAPN2 | 0.5 | 0.02636 | -0.31 | 0.05176 | mirMAP | -0.11 | 0.00157 | NA | |
| 42 | hsa-miR-20a-3p | CAPN2 | 2.52 | 0 | -0.31 | 0.05176 | MirTarget | -0.13 | 0 | NA | |
| 43 | hsa-miR-320b | CAPN2 | 0.23 | 0.37882 | -0.31 | 0.05176 | miRanda | -0.12 | 1.0E-5 | NA | |
| 44 | hsa-miR-421 | CAPN2 | 0.17 | 0.53528 | -0.31 | 0.05176 | miRanda | -0.16 | 0 | NA | |
| 45 | hsa-miR-590-5p | CAPN2 | 2.07 | 0 | -0.31 | 0.05176 | miRanda | -0.16 | 0 | NA | |
| 46 | hsa-miR-148b-5p | CASP10 | 1.39 | 0 | -0.27 | 0.09806 | mirMAP | -0.14 | 2.0E-5 | NA | |
| 47 | hsa-miR-19a-3p | CASP10 | 2.12 | 0 | -0.27 | 0.09806 | MirTarget; mirMAP | -0.1 | 6.0E-5 | NA | |
| 48 | hsa-miR-19b-1-5p | CASP10 | 1.71 | 0 | -0.27 | 0.09806 | mirMAP | -0.18 | 0 | NA | |
| 49 | hsa-miR-19b-3p | CASP10 | 2.11 | 0 | -0.27 | 0.09806 | MirTarget; mirMAP | -0.12 | 0.00012 | NA | |
| 50 | hsa-miR-421 | CASP10 | 0.17 | 0.53528 | -0.27 | 0.09806 | mirMAP | -0.17 | 0 | NA | |
| 51 | hsa-miR-744-3p | CASP10 | 2.07 | 0 | -0.27 | 0.09806 | mirMAP | -0.13 | 0 | NA | |
| 52 | hsa-miR-139-5p | CASP3 | -2.27 | 0 | 0.75 | 0 | miRanda | -0.1 | 0 | NA | |
| 53 | hsa-miR-195-3p | CASP3 | -1.33 | 0 | 0.75 | 0 | MirTarget | -0.12 | 0 | NA | |
| 54 | hsa-miR-30c-5p | CASP3 | -0.33 | 0.1236 | 0.75 | 0 | miRNATAP | -0.15 | 0 | NA | |
| 55 | hsa-miR-30d-5p | CASP3 | -0.92 | 4.0E-5 | 0.75 | 0 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.17 | 0 | NA | |
| 56 | hsa-miR-125a-5p | CASP6 | -1.05 | 0 | 0.9 | 0 | miRanda | -0.12 | 0.00016 | NA | |
| 57 | hsa-miR-664a-3p | CASP7 | 0.44 | 0.02142 | -0.21 | 0.08139 | MirTarget | -0.11 | 0.00018 | NA | |
| 58 | hsa-miR-107 | CFLAR | 0.66 | 0 | -0.6 | 0.00015 | miRanda | -0.15 | 0.00732 | NA | |
| 59 | hsa-miR-130b-3p | CFLAR | 1.83 | 0 | -0.6 | 0.00015 | mirMAP | -0.17 | 0 | NA | |
| 60 | hsa-miR-320b | CFLAR | 0.23 | 0.37882 | -0.6 | 0.00015 | miRanda | -0.15 | 0 | NA | |
| 61 | hsa-miR-421 | CFLAR | 0.17 | 0.53528 | -0.6 | 0.00015 | miRanda | -0.11 | 0.00019 | NA | |
| 62 | hsa-miR-454-3p | CFLAR | 1.49 | 0 | -0.6 | 0.00015 | mirMAP | -0.11 | 0.0011 | NA | |
| 63 | hsa-miR-708-5p | CFLAR | 3.04 | 0 | -0.6 | 0.00015 | mirMAP | -0.1 | 2.0E-5 | NA | |
| 64 | hsa-miR-15a-5p | CHUK | 1.63 | 0 | 0.04 | 0.74424 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.16 | 0 | NA | |
| 65 | hsa-miR-29b-2-5p | CHUK | 0.35 | 0.19484 | 0.04 | 0.74424 | MirTarget | -0.12 | 0 | NA | |
| 66 | hsa-miR-339-5p | CHUK | 0.54 | 0.04881 | 0.04 | 0.74424 | miRanda | -0.1 | 0 | NA | |
| 67 | hsa-miR-342-3p | CHUK | -0.13 | 0.56103 | 0.04 | 0.74424 | miRanda | -0.18 | 0 | NA | |
| 68 | hsa-miR-497-5p | CHUK | -0.05 | 0.78621 | 0.04 | 0.74424 | MirTarget | -0.19 | 0 | NA | |
| 69 | hsa-miR-15b-3p | CSF2RB | 0.8 | 0.0004 | -1.28 | 0 | mirMAP | -0.15 | 0.00822 | NA | |
| 70 | hsa-miR-181d-5p | CSF2RB | 1.19 | 0 | -1.28 | 0 | MirTarget | -0.23 | 8.0E-5 | NA | |
| 71 | hsa-miR-19a-3p | CSF2RB | 2.12 | 0 | -1.28 | 0 | MirTarget | -0.17 | 4.0E-5 | NA | |
| 72 | hsa-miR-19b-3p | CSF2RB | 2.11 | 0 | -1.28 | 0 | MirTarget | -0.25 | 0 | NA | |
| 73 | hsa-miR-139-5p | CYCS | -2.27 | 0 | 0.53 | 0.0008 | miRanda | -0.18 | 0 | NA | |
| 74 | hsa-miR-342-3p | CYCS | -0.13 | 0.56103 | 0.53 | 0.0008 | mirMAP | -0.1 | 0.00171 | NA | |
| 75 | hsa-miR-342-3p | DFFA | -0.13 | 0.56103 | 0.21 | 0.04672 | mirMAP | -0.12 | 0 | NA | |
| 76 | hsa-miR-664a-3p | DFFA | 0.44 | 0.02142 | 0.21 | 0.04672 | mirMAP | -0.11 | 1.0E-5 | NA | |
| 77 | hsa-miR-365a-3p | DFFB | 0.01 | 0.9536 | 0.55 | 2.0E-5 | MirTarget | -0.12 | 0 | NA | |
| 78 | hsa-miR-130a-3p | ENDOD1 | 0.88 | 0.00016 | 0.06 | 0.80229 | MirTarget | -0.16 | 0.00041 | NA | |
| 79 | hsa-miR-130b-3p | ENDOD1 | 1.83 | 0 | 0.06 | 0.80229 | MirTarget | -0.21 | 0 | NA | |
| 80 | hsa-miR-193a-3p | ENDOD1 | 0.55 | 0.0319 | 0.06 | 0.80229 | miRanda | -0.18 | 6.0E-5 | NA | |
| 81 | hsa-miR-193b-3p | ENDOD1 | 1.1 | 0.00082 | 0.06 | 0.80229 | miRNAWalker2 validate | -0.19 | 0 | NA | |
| 82 | hsa-miR-19a-3p | ENDOD1 | 2.12 | 0 | 0.06 | 0.80229 | mirMAP | -0.24 | 0 | NA | |
| 83 | hsa-miR-19b-3p | ENDOD1 | 2.11 | 0 | 0.06 | 0.80229 | mirMAP | -0.21 | 0 | NA | |
| 84 | hsa-miR-20a-3p | ENDOD1 | 2.52 | 0 | 0.06 | 0.80229 | MirTarget | -0.26 | 0 | NA | |
| 85 | hsa-miR-26b-3p | ENDOD1 | 1.37 | 0 | 0.06 | 0.80229 | mirMAP | -0.16 | 0.00018 | NA | |
| 86 | hsa-miR-301a-3p | ENDOD1 | 2.7 | 0 | 0.06 | 0.80229 | MirTarget | -0.12 | 0.00101 | NA | |
| 87 | hsa-miR-330-5p | ENDOD1 | 0.17 | 0.33643 | 0.06 | 0.80229 | miRanda | -0.18 | 0.00348 | NA | |
| 88 | hsa-miR-454-3p | ENDOD1 | 1.49 | 0 | 0.06 | 0.80229 | MirTarget | -0.2 | 4.0E-5 | NA | |
| 89 | hsa-miR-590-3p | ENDOD1 | 0.84 | 0.00129 | 0.06 | 0.80229 | miRanda | -0.14 | 0.00426 | NA | |
| 90 | hsa-miR-24-3p | EXOG | -0.04 | 0.78587 | -0.19 | 0.08402 | MirTarget | -0.1 | 0.00598 | NA | |
| 91 | hsa-miR-106a-5p | FAS | 1.39 | 6.0E-5 | -0.88 | 0.00034 | miRNAWalker2 validate; miRTarBase | -0.27 | 0 | 22431000; 27142596 | miR 106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS; Bioinformatic analysis combining with validation experiments identified FAS as a direct target of miR-106a; Moreover a significant inverse correlation was found between miR-106a and FAS expression not only in gastric cancer cell lines but also in gastric cancer specimens; Taken together these findings suggest that ectopicly overexpressed miR-106a may play an oncogenic role in gastric carcinogenesis and impair extrinsic apoptotic pathway through targeting FAS;Functional experiment ascertained that miR-106a interacted with FAS and mediated caspase3 pathway |
| 92 | hsa-miR-590-5p | FAS | 2.07 | 0 | -0.88 | 0.00034 | miRanda | -0.28 | 0 | NA | |
| 93 | hsa-let-7e-5p | FASLG | -0.75 | 7.0E-5 | 0.23 | 0.52524 | miRNATAP | -0.24 | 0.0052 | NA | |
| 94 | hsa-miR-107 | IKBKG | 0.66 | 0 | 0.08 | 0.54471 | miRanda | -0.13 | 0.00969 | NA | |
| 95 | hsa-miR-143-3p | IKBKG | -1.21 | 1.0E-5 | 0.08 | 0.54471 | mirMAP | -0.16 | 0 | NA | |
| 96 | hsa-miR-17-3p | IKBKG | 1.37 | 0 | 0.08 | 0.54471 | mirMAP | -0.12 | 0.00016 | NA | |
| 97 | hsa-miR-24-3p | IKBKG | -0.04 | 0.78587 | 0.08 | 0.54471 | mirMAP | -0.14 | 0.00373 | NA | |
| 98 | hsa-miR-330-3p | IKBKG | -0.72 | 0.0008 | 0.08 | 0.54471 | mirMAP | -0.17 | 0 | NA | |
| 99 | hsa-miR-141-3p | IL1A | 3.37 | 0 | -2.79 | 0 | MirTarget | -0.43 | 0 | NA | |
| 100 | hsa-miR-181c-5p | IL1A | 0.53 | 0.01259 | -2.79 | 0 | MirTarget | -0.42 | 4.0E-5 | NA | |
| 101 | hsa-miR-181d-5p | IL1A | 1.19 | 0 | -2.79 | 0 | MirTarget | -0.5 | 0 | NA | |
| 102 | hsa-miR-200a-3p | IL1A | 3.15 | 0 | -2.79 | 0 | MirTarget | -0.45 | 0 | NA | |
| 103 | hsa-miR-30b-5p | IL1A | 0.36 | 0.13803 | -2.79 | 0 | MirTarget | -0.37 | 3.0E-5 | NA | |
| 104 | hsa-miR-30d-5p | IL1A | -0.92 | 4.0E-5 | -2.79 | 0 | MirTarget | -0.36 | 0.00024 | NA | |
| 105 | hsa-miR-30e-5p | IL1A | 1.6 | 0 | -2.79 | 0 | MirTarget | -0.39 | 0.00095 | NA | |
| 106 | hsa-miR-335-5p | IL1A | -0.47 | 0.0677 | -2.79 | 0 | miRNAWalker2 validate | -0.36 | 0.00013 | NA | |
| 107 | hsa-miR-664a-3p | IL1A | 0.44 | 0.02142 | -2.79 | 0 | MirTarget | -0.4 | 0.00041 | NA | |
| 108 | hsa-miR-7-1-3p | IL1B | 2.61 | 0 | -1.42 | 1.0E-5 | MirTarget | -0.2 | 0.00249 | NA | |
| 109 | hsa-miR-130b-5p | IL1R1 | 1.54 | 0 | -0.9 | 1.0E-5 | mirMAP | -0.21 | 0 | NA | |
| 110 | hsa-miR-17-3p | IL1R1 | 1.37 | 0 | -0.9 | 1.0E-5 | mirMAP | -0.29 | 0 | NA | |
| 111 | hsa-miR-186-5p | IL1R1 | 0.85 | 0 | -0.9 | 1.0E-5 | mirMAP | -0.33 | 0 | NA | |
| 112 | hsa-miR-26b-5p | IL1R1 | 0.72 | 5.0E-5 | -0.9 | 1.0E-5 | mirMAP | -0.15 | 0.00501 | NA | |
| 113 | hsa-miR-335-3p | IL1R1 | 1.51 | 0 | -0.9 | 1.0E-5 | mirMAP | -0.29 | 0 | NA | |
| 114 | hsa-miR-590-3p | IL1R1 | 0.84 | 0.00129 | -0.9 | 1.0E-5 | miRanda; miRNATAP | -0.17 | 0.00014 | NA | |
| 115 | hsa-miR-139-5p | IL1RAP | -2.27 | 0 | 0 | 0.99919 | miRanda | -0.12 | 0.00188 | NA | |
| 116 | hsa-miR-17-5p | IL1RAP | 2.07 | 0 | 0 | 0.99919 | MirTarget; TargetScan | -0.2 | 1.0E-5 | NA | |
| 117 | hsa-miR-186-5p | IL1RAP | 0.85 | 0 | 0 | 0.99919 | mirMAP | -0.22 | 0.0056 | NA | |
| 118 | hsa-miR-19a-3p | IL1RAP | 2.12 | 0 | 0 | 0.99919 | MirTarget | -0.2 | 0 | NA | |
| 119 | hsa-miR-19b-3p | IL1RAP | 2.11 | 0 | 0 | 0.99919 | MirTarget | -0.23 | 0 | NA | |
| 120 | hsa-miR-204-5p | IL1RAP | -1.02 | 0.00767 | 0 | 0.99919 | miRNAWalker2 validate | -0.11 | 0.00018 | NA | |
| 121 | hsa-miR-20a-5p | IL1RAP | 2.65 | 0 | 0 | 0.99919 | MirTarget | -0.21 | 0 | NA | |
| 122 | hsa-miR-29a-3p | IL1RAP | 0.1 | 0.5732 | 0 | 0.99919 | MirTarget; miRNATAP | -0.19 | 0.00191 | NA | |
| 123 | hsa-miR-29b-3p | IL1RAP | 3.11 | 0 | 0 | 0.99919 | MirTarget; miRNATAP | -0.2 | 0 | NA | |
| 124 | hsa-miR-29c-3p | IL1RAP | 1.32 | 0 | 0 | 0.99919 | MirTarget; miRNATAP | -0.17 | 9.0E-5 | NA | |
| 125 | hsa-miR-375 | IL1RAP | 0.62 | 0.1492 | 0 | 0.99919 | miRNAWalker2 validate; miRanda | -0.14 | 0 | NA | |
| 126 | hsa-miR-454-3p | IL1RAP | 1.49 | 0 | 0 | 0.99919 | MirTarget | -0.13 | 0.0096 | NA | |
| 127 | hsa-miR-576-5p | IL1RAP | 1.03 | 0 | 0 | 0.99919 | mirMAP | -0.15 | 0.00382 | NA | |
| 128 | hsa-miR-582-5p | IL1RAP | 1.08 | 0.00149 | 0 | 0.99919 | MirTarget | -0.14 | 2.0E-5 | NA | |
| 129 | hsa-miR-664a-3p | IL1RAP | 0.44 | 0.02142 | 0 | 0.99919 | mirMAP | -0.15 | 0.00816 | NA | |
| 130 | hsa-miR-95-3p | IL1RAP | -0.19 | 0.53374 | 0 | 0.99919 | MirTarget | -0.13 | 0.00034 | NA | |
| 131 | hsa-miR-146a-5p | IRAK1 | 0.68 | 0.01053 | 1.11 | 0 | miRNAWalker2 validate; miRTarBase | -0.1 | 0.00015 | 25242818; 22846912; 21632853 | Interestingly re-expression of miR-146a inhibited the invasive capacity of Colo357 and Panc-1 PC cells with concomitant down-regulation of EGFR and IRAK-1; Most importantly we found that the treatment of PC cells with "natural agents" 33'-diinodolylmethane DIM or isoflavone led to an increase in the expression of miR-146a and consequently down-regulated the expression of EGFR MTA-2 IRAK-1 and NF-κB resulting in the inhibition of invasion of Colo357 and Panc-1 cells;Functional analysis revealed that miR-146a rs2910164 C allele inhibited cell proliferation and significantly downregulated expression of IRAK1 and TRAF6 in bladder cancer cells;The regulation of EGFR and IRAK1 by miR-146a was examined with miR-146a-transfected gastric cancer cells; Ectopic expression of miR-146a inhibited migration and invasion and downregulated EGFR and IRAK1 expression in gastric cancer cells; MiR-146a targeting of EGFR and IRAK1 is an independent prognostic factor in gastric cancer cases |
| 132 | hsa-miR-335-5p | IRAK2 | -0.47 | 0.0677 | 0.57 | 0.0153 | miRNAWalker2 validate | -0.17 | 0.00046 | NA | |
| 133 | hsa-miR-141-3p | IRAK3 | 3.37 | 0 | -1.32 | 1.0E-5 | mirMAP | -0.15 | 0.00115 | NA | |
| 134 | hsa-miR-20a-3p | IRAK3 | 2.52 | 0 | -1.32 | 1.0E-5 | mirMAP | -0.19 | 0.00017 | NA | |
| 135 | hsa-miR-21-5p | IRAK3 | 4.38 | 0 | -1.32 | 1.0E-5 | mirMAP | -0.2 | 0.00012 | NA | |
| 136 | hsa-miR-25-3p | IRAK3 | 0.36 | 0.01637 | -1.32 | 1.0E-5 | mirMAP | -0.24 | 0.00982 | NA | |
| 137 | hsa-miR-3200-3p | IRAK3 | 0.52 | 0.13499 | -1.32 | 1.0E-5 | mirMAP | -0.15 | 0.0003 | NA | |
| 138 | hsa-miR-324-5p | IRAK3 | 1.07 | 5.0E-5 | -1.32 | 1.0E-5 | miRanda | -0.14 | 0.00752 | NA | |
| 139 | hsa-miR-335-3p | IRAK3 | 1.51 | 0 | -1.32 | 1.0E-5 | mirMAP | -0.45 | 0 | NA | |
| 140 | hsa-miR-33a-5p | IRAK3 | 2.8 | 0 | -1.32 | 1.0E-5 | mirMAP | -0.13 | 0.00174 | NA | |
| 141 | hsa-miR-450b-5p | IRAK3 | 1.69 | 0 | -1.32 | 1.0E-5 | mirMAP | -0.18 | 0.00016 | NA | |
| 142 | hsa-miR-589-3p | IRAK3 | 1.34 | 2.0E-5 | -1.32 | 1.0E-5 | mirMAP | -0.13 | 0.00423 | NA | |
| 143 | hsa-miR-590-5p | IRAK3 | 2.07 | 0 | -1.32 | 1.0E-5 | mirMAP | -0.23 | 0.00014 | NA | |
| 144 | hsa-miR-106b-5p | MAP3K14 | 1.47 | 0 | -0.51 | 0.00539 | MirTarget | -0.15 | 0.00033 | NA | |
| 145 | hsa-miR-17-3p | MAP3K14 | 1.37 | 0 | -0.51 | 0.00539 | MirTarget | -0.16 | 0.00023 | NA | |
| 146 | hsa-miR-365a-3p | MYD88 | 0.01 | 0.9536 | -0.59 | 0 | MirTarget | -0.12 | 0 | NA | |
| 147 | hsa-miR-429 | MYD88 | 2.38 | 0 | -0.59 | 0 | miRanda | -0.11 | 0 | NA | |
| 148 | hsa-miR-671-5p | NFKB1 | 2.24 | 0 | -0.34 | 0.00609 | MirTarget | -0.1 | 0 | NA | |
| 149 | hsa-miR-185-3p | NTRK1 | -0.38 | 0.09365 | -1.2 | 0.00018 | MirTarget | -0.22 | 0.00087 | NA | |
| 150 | hsa-miR-186-5p | PIK3CA | 0.85 | 0 | -0.34 | 0.01077 | mirMAP | -0.16 | 0.00027 | NA |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 37 | 1929 | 3.349e-24 | 5.194e-21 |
| 2 | CELL DEATH | 30 | 1001 | 2.415e-24 | 5.194e-21 |
| 3 | REGULATION OF CELL DEATH | 34 | 1472 | 2.089e-24 | 5.194e-21 |
| 4 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 36 | 1848 | 1.302e-23 | 1.515e-20 |
| 5 | INTRACELLULAR SIGNAL TRANSDUCTION | 34 | 1572 | 1.773e-23 | 1.65e-20 |
| 6 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 32 | 1381 | 9.296e-23 | 7.209e-20 |
| 7 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 14 | 99 | 1.317e-20 | 8.755e-18 |
| 8 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 31 | 1492 | 1.535e-20 | 8.927e-18 |
| 9 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 33 | 1791 | 1.764e-20 | 9.12e-18 |
| 10 | IMMUNE SYSTEM PROCESS | 34 | 1984 | 3.162e-20 | 1.291e-17 |
| 11 | POSITIVE REGULATION OF CELL COMMUNICATION | 31 | 1532 | 3.328e-20 | 1.291e-17 |
| 12 | RESPONSE TO CYTOKINE | 24 | 714 | 3.115e-20 | 1.291e-17 |
| 13 | NEGATIVE REGULATION OF CELL DEATH | 25 | 872 | 1.826e-19 | 6.535e-17 |
| 14 | POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 15 | 179 | 1.661e-18 | 5.52e-16 |
| 15 | RESPONSE TO NITROGEN COMPOUND | 24 | 859 | 2.218e-18 | 6.879e-16 |
| 16 | APOPTOTIC SIGNALING PATHWAY | 17 | 289 | 2.707e-18 | 7.874e-16 |
| 17 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 29 | 1518 | 4.863e-18 | 1.331e-15 |
| 18 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 10 | 39 | 9.164e-18 | 2.369e-15 |
| 19 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 15 | 213 | 2.327e-17 | 5.698e-15 |
| 20 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 16 | 279 | 4.637e-17 | 1.079e-14 |
| 21 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 23 | 876 | 5.512e-17 | 1.221e-14 |
| 22 | REGULATION OF KINASE ACTIVITY | 22 | 776 | 6.5e-17 | 1.375e-14 |
| 23 | REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 15 | 233 | 8.981e-17 | 1.817e-14 |
| 24 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 25 | 1135 | 9.425e-17 | 1.827e-14 |
| 25 | CELLULAR RESPONSE TO CYTOKINE STIMULUS | 20 | 606 | 1.328e-16 | 2.471e-14 |
| 26 | CYTOKINE MEDIATED SIGNALING PATHWAY | 18 | 452 | 2.334e-16 | 4.177e-14 |
| 27 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 18 | 470 | 4.617e-16 | 7.957e-14 |
| 28 | REGULATION OF IMMUNE RESPONSE | 22 | 858 | 5.289e-16 | 8.789e-14 |
| 29 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 28 | 1656 | 5.74e-16 | 9.21e-14 |
| 30 | POSITIVE REGULATION OF KINASE ACTIVITY | 18 | 482 | 7.166e-16 | 1.111e-13 |
| 31 | REGULATION OF IMMUNE SYSTEM PROCESS | 26 | 1403 | 1.163e-15 | 1.746e-13 |
| 32 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 11 | 95 | 2.358e-15 | 3.428e-13 |
| 33 | REGULATION OF TRANSFERASE ACTIVITY | 22 | 946 | 3.986e-15 | 5.621e-13 |
| 34 | PHOSPHORYLATION | 24 | 1228 | 7.026e-15 | 9.615e-13 |
| 35 | POSITIVE REGULATION OF IMMUNE RESPONSE | 18 | 563 | 1.055e-14 | 1.403e-12 |
| 36 | REGULATION OF PROTEIN MODIFICATION PROCESS | 27 | 1710 | 1.334e-14 | 1.725e-12 |
| 37 | ZYMOGEN ACTIVATION | 11 | 112 | 1.528e-14 | 1.922e-12 |
| 38 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 22 | 1036 | 2.569e-14 | 2.988e-12 |
| 39 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 20 | 799 | 2.545e-14 | 2.988e-12 |
| 40 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 22 | 1036 | 2.569e-14 | 2.988e-12 |
| 41 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 17 | 505 | 2.904e-14 | 3.296e-12 |
| 42 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 26 | 1618 | 3.461e-14 | 3.834e-12 |
| 43 | PROTEIN PHOSPHORYLATION | 21 | 944 | 4.835e-14 | 5.219e-12 |
| 44 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 18 | 616 | 4.936e-14 | 5.219e-12 |
| 45 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 28 | 1977 | 5.204e-14 | 5.381e-12 |
| 46 | RESPONSE TO TUMOR NECROSIS FACTOR | 13 | 233 | 8.099e-14 | 8.193e-12 |
| 47 | INFLAMMATORY RESPONSE | 16 | 454 | 9.433e-14 | 9.339e-12 |
| 48 | POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 11 | 132 | 9.662e-14 | 9.366e-12 |
| 49 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 10 | 98 | 1.779e-13 | 1.689e-11 |
| 50 | REGULATION OF PEPTIDASE ACTIVITY | 15 | 392 | 1.935e-13 | 1.8e-11 |
| 51 | RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 14 | 321 | 2.346e-13 | 2.141e-11 |
| 52 | RESPONSE TO ENDOGENOUS STIMULUS | 24 | 1450 | 2.699e-13 | 2.415e-11 |
| 53 | I KAPPAB KINASE NF KAPPAB SIGNALING | 9 | 70 | 3.64e-13 | 3.196e-11 |
| 54 | POSITIVE REGULATION OF PEPTIDASE ACTIVITY | 11 | 154 | 5.351e-13 | 4.571e-11 |
| 55 | POSITIVE REGULATION OF CELL DEATH | 17 | 605 | 5.403e-13 | 4.571e-11 |
| 56 | ACTIVATION OF IMMUNE RESPONSE | 15 | 427 | 6.653e-13 | 5.528e-11 |
| 57 | TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 10 | 118 | 1.186e-12 | 9.681e-11 |
| 58 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 19 | 867 | 1.4e-12 | 1.123e-10 |
| 59 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 12 | 228 | 1.622e-12 | 1.279e-10 |
| 60 | NIK NF KAPPAB SIGNALING | 9 | 83 | 1.789e-12 | 1.387e-10 |
| 61 | RESPONSE TO ABIOTIC STIMULUS | 20 | 1024 | 2.537e-12 | 1.935e-10 |
| 62 | RESPONSE TO EXTERNAL STIMULUS | 25 | 1821 | 4.561e-12 | 3.423e-10 |
| 63 | REGULATION OF PROTEOLYSIS | 17 | 711 | 7.078e-12 | 5.228e-10 |
| 64 | IMMUNE RESPONSE | 20 | 1100 | 9.35e-12 | 6.798e-10 |
| 65 | PROTEIN MATURATION | 12 | 265 | 9.513e-12 | 6.81e-10 |
| 66 | RESPONSE TO BACTERIUM | 15 | 528 | 1.377e-11 | 9.707e-10 |
| 67 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 10 | 153 | 1.619e-11 | 1.124e-09 |
| 68 | RESPONSE TO BIOTIC STIMULUS | 18 | 886 | 2.209e-11 | 1.505e-09 |
| 69 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 13 | 363 | 2.231e-11 | 1.505e-09 |
| 70 | POSITIVE REGULATION OF DEFENSE RESPONSE | 13 | 364 | 2.309e-11 | 1.535e-09 |
| 71 | RESPONSE TO WOUNDING | 15 | 563 | 3.403e-11 | 2.23e-09 |
| 72 | REGULATION OF MAP KINASE ACTIVITY | 12 | 319 | 8.211e-11 | 5.306e-09 |
| 73 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 12 | 323 | 9.48e-11 | 6.043e-09 |
| 74 | TOLL LIKE RECEPTOR SIGNALING PATHWAY | 8 | 85 | 1.06e-10 | 6.666e-09 |
| 75 | EXECUTION PHASE OF APOPTOSIS | 7 | 55 | 1.904e-10 | 1.181e-08 |
| 76 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 5 | 13 | 1.987e-10 | 1.217e-08 |
| 77 | NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 10 | 200 | 2.291e-10 | 1.384e-08 |
| 78 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 9 | 142 | 2.391e-10 | 1.427e-08 |
| 79 | REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 9 | 144 | 2.71e-10 | 1.596e-08 |
| 80 | ACTIVATION OF INNATE IMMUNE RESPONSE | 10 | 204 | 2.781e-10 | 1.618e-08 |
| 81 | POSITIVE REGULATION OF PROTEOLYSIS | 12 | 363 | 3.62e-10 | 2.08e-08 |
| 82 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 12 | 365 | 3.855e-10 | 2.187e-08 |
| 83 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 11 | 289 | 4.853e-10 | 2.721e-08 |
| 84 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 6 | 34 | 5.168e-10 | 2.863e-08 |
| 85 | POSITIVE REGULATION OF MAPK CASCADE | 13 | 470 | 5.398e-10 | 2.921e-08 |
| 86 | WOUND HEALING | 13 | 470 | 5.398e-10 | 2.921e-08 |
| 87 | PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 8 | 109 | 7.942e-10 | 4.248e-08 |
| 88 | POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 5 | 17 | 9.471e-10 | 5.008e-08 |
| 89 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 9 | 171 | 1.25e-09 | 6.538e-08 |
| 90 | REGULATION OF RESPONSE TO STRESS | 20 | 1468 | 1.578e-09 | 8.085e-08 |
| 91 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 17 | 1008 | 1.581e-09 | 8.085e-08 |
| 92 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 10 | 246 | 1.717e-09 | 8.685e-08 |
| 93 | RESPONSE TO LIPID | 16 | 888 | 2.086e-09 | 1.044e-07 |
| 94 | REGULATION OF DEFENSE RESPONSE | 15 | 759 | 2.123e-09 | 1.051e-07 |
| 95 | HOMEOSTATIC PROCESS | 19 | 1337 | 2.31e-09 | 1.12e-07 |
| 96 | CELLULAR COMPONENT DISASSEMBLY INVOLVED IN EXECUTION PHASE OF APOPTOSIS | 6 | 43 | 2.297e-09 | 1.12e-07 |
| 97 | CELLULAR RESPONSE TO MECHANICAL STIMULUS | 7 | 80 | 2.821e-09 | 1.353e-07 |
| 98 | REGULATION OF MAPK CASCADE | 14 | 660 | 3.283e-09 | 1.559e-07 |
| 99 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 5 | 22 | 3.987e-09 | 1.874e-07 |
| 100 | REGULATION OF INNATE IMMUNE RESPONSE | 11 | 357 | 4.453e-09 | 2.051e-07 |
| 101 | DEFENSE RESPONSE | 18 | 1231 | 4.431e-09 | 2.051e-07 |
| 102 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 6 | 49 | 5.2e-09 | 2.372e-07 |
| 103 | REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 6 | 50 | 5.896e-09 | 2.664e-07 |
| 104 | FC RECEPTOR SIGNALING PATHWAY | 9 | 206 | 6.426e-09 | 2.875e-07 |
| 105 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 6 | 51 | 6.668e-09 | 2.942e-07 |
| 106 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 9 | 207 | 6.703e-09 | 2.942e-07 |
| 107 | PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 5 | 25 | 7.992e-09 | 3.475e-07 |
| 108 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 6 | 55 | 1.064e-08 | 4.584e-07 |
| 109 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 8 | 152 | 1.115e-08 | 4.76e-07 |
| 110 | CHEMICAL HOMEOSTASIS | 15 | 874 | 1.42e-08 | 6.008e-07 |
| 111 | NECROTIC CELL DEATH | 5 | 28 | 1.469e-08 | 6.157e-07 |
| 112 | RESPONSE TO PEPTIDE | 11 | 404 | 1.599e-08 | 6.643e-07 |
| 113 | POSITIVE REGULATION OF NIK NF KAPPAB SIGNALING | 5 | 29 | 1.771e-08 | 7.292e-07 |
| 114 | RESPONSE TO HORMONE | 15 | 893 | 1.891e-08 | 7.72e-07 |
| 115 | POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 4 | 11 | 1.927e-08 | 7.797e-07 |
| 116 | PROTEOLYSIS | 17 | 1208 | 2.361e-08 | 9.471e-07 |
| 117 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 5 | 32 | 2.984e-08 | 1.187e-06 |
| 118 | SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 5 | 33 | 3.509e-08 | 1.372e-06 |
| 119 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 5 | 33 | 3.509e-08 | 1.372e-06 |
| 120 | RESPONSE TO INTERLEUKIN 1 | 7 | 115 | 3.604e-08 | 1.397e-06 |
| 121 | INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 4 | 13 | 4.158e-08 | 1.599e-06 |
| 122 | NEURON APOPTOTIC PROCESS | 5 | 35 | 4.779e-08 | 1.823e-06 |
| 123 | PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 7 | 120 | 4.839e-08 | 1.831e-06 |
| 124 | RESPONSE TO OXIDATIVE STRESS | 10 | 352 | 5.201e-08 | 1.952e-06 |
| 125 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 9 | 264 | 5.494e-08 | 2.045e-06 |
| 126 | INOSITOL LIPID MEDIATED SIGNALING | 7 | 124 | 6.07e-08 | 2.242e-06 |
| 127 | CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 6 | 74 | 6.522e-08 | 2.389e-06 |
| 128 | RESPONSE TO REACTIVE OXYGEN SPECIES | 8 | 191 | 6.617e-08 | 2.405e-06 |
| 129 | CELLULAR GLUCOSE HOMEOSTASIS | 6 | 75 | 7.073e-08 | 2.551e-06 |
| 130 | CELLULAR RESPONSE TO PEPTIDE | 9 | 274 | 7.55e-08 | 2.702e-06 |
| 131 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 8 | 195 | 7.766e-08 | 2.758e-06 |
| 132 | RESPONSE TO INORGANIC SUBSTANCE | 11 | 479 | 9.058e-08 | 3.193e-06 |
| 133 | REGULATION OF HYDROLASE ACTIVITY | 17 | 1327 | 9.294e-08 | 3.252e-06 |
| 134 | REGULATION OF NIK NF KAPPAB SIGNALING | 5 | 42 | 1.233e-07 | 4.283e-06 |
| 135 | REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 4 | 17 | 1.372e-07 | 4.604e-06 |
| 136 | ACTIVATION OF NF KAPPAB INDUCING KINASE ACTIVITY | 4 | 17 | 1.372e-07 | 4.604e-06 |
| 137 | REGULATION OF INFLAMMATORY RESPONSE | 9 | 294 | 1.375e-07 | 4.604e-06 |
| 138 | RESPONSE TO MECHANICAL STIMULUS | 8 | 210 | 1.374e-07 | 4.604e-06 |
| 139 | ACTIVATION OF PROTEIN KINASE A ACTIVITY | 4 | 17 | 1.372e-07 | 4.604e-06 |
| 140 | POSITIVE REGULATION OF GENE EXPRESSION | 19 | 1733 | 1.531e-07 | 5.088e-06 |
| 141 | REGULATION OF CELL ADHESION | 12 | 629 | 1.635e-07 | 5.394e-06 |
| 142 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 14 | 905 | 1.706e-07 | 5.591e-06 |
| 143 | CELLULAR RESPONSE TO INTERLEUKIN 1 | 6 | 88 | 1.85e-07 | 6.02e-06 |
| 144 | T CELL RECEPTOR SIGNALING PATHWAY | 7 | 146 | 1.863e-07 | 6.02e-06 |
| 145 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 5 | 46 | 1.97e-07 | 6.322e-06 |
| 146 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 14 | 917 | 2.004e-07 | 6.386e-06 |
| 147 | RESPONSE TO OXYGEN LEVELS | 9 | 311 | 2.213e-07 | 6.911e-06 |
| 148 | NEURON DEATH | 5 | 47 | 2.2e-07 | 6.911e-06 |
| 149 | HEMOSTASIS | 9 | 311 | 2.213e-07 | 6.911e-06 |
| 150 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 15 | 1079 | 2.253e-07 | 6.989e-06 |
| 151 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 6 | 95 | 2.922e-07 | 9.005e-06 |
| 152 | RESPONSE TO NICOTINE | 5 | 51 | 3.34e-07 | 1.022e-05 |
| 153 | NECROPTOTIC PROCESS | 4 | 21 | 3.422e-07 | 1.041e-05 |
| 154 | CELLULAR RESPONSE TO HORMONE STIMULUS | 11 | 552 | 3.745e-07 | 1.124e-05 |
| 155 | LIPID PHOSPHORYLATION | 6 | 99 | 3.735e-07 | 1.124e-05 |
| 156 | RENAL SYSTEM PROCESS | 6 | 102 | 4.459e-07 | 1.33e-05 |
| 157 | REGULATION OF CYTOKINE PRODUCTION | 11 | 563 | 4.553e-07 | 1.349e-05 |
| 158 | STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 6 | 103 | 4.724e-07 | 1.391e-05 |
| 159 | RESPONSE TO CARBOHYDRATE | 7 | 168 | 4.835e-07 | 1.415e-05 |
| 160 | CELL ACTIVATION | 11 | 568 | 4.968e-07 | 1.445e-05 |
| 161 | POSITIVE REGULATION OF PROTEIN IMPORT | 6 | 104 | 5.003e-07 | 1.446e-05 |
| 162 | REGULATION OF CELL PROLIFERATION | 17 | 1496 | 5.142e-07 | 1.477e-05 |
| 163 | REGULATION OF NEURON DEATH | 8 | 252 | 5.513e-07 | 1.574e-05 |
| 164 | LEUKOCYTE CELL CELL ADHESION | 8 | 255 | 6.028e-07 | 1.71e-05 |
| 165 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 9 | 360 | 7.542e-07 | 2.127e-05 |
| 166 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 8 | 263 | 7.61e-07 | 2.133e-05 |
| 167 | RESPONSE TO AMINO ACID | 6 | 112 | 7.751e-07 | 2.159e-05 |
| 168 | DEVELOPMENTAL PROGRAMMED CELL DEATH | 4 | 26 | 8.457e-07 | 2.328e-05 |
| 169 | REGULATION OF NECROTIC CELL DEATH | 4 | 26 | 8.457e-07 | 2.328e-05 |
| 170 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 9 | 370 | 9.468e-07 | 2.592e-05 |
| 171 | CELLULAR RESPONSE TO STRESS | 17 | 1565 | 9.671e-07 | 2.631e-05 |
| 172 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 8 | 272 | 9.802e-07 | 2.652e-05 |
| 173 | DNA CATABOLIC PROCESS | 4 | 27 | 9.906e-07 | 2.664e-05 |
| 174 | NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY | 4 | 28 | 1.153e-06 | 3.084e-05 |
| 175 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 6 | 121 | 1.221e-06 | 3.246e-05 |
| 176 | PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 7 | 193 | 1.229e-06 | 3.249e-05 |
| 177 | REGULATION OF LIPID METABOLIC PROCESS | 8 | 282 | 1.285e-06 | 3.378e-05 |
| 178 | MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 4 | 30 | 1.537e-06 | 4.018e-05 |
| 179 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 6 | 126 | 1.547e-06 | 4.022e-05 |
| 180 | LEUKOCYTE DIFFERENTIATION | 8 | 292 | 1.667e-06 | 4.309e-05 |
| 181 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 10 | 514 | 1.682e-06 | 4.324e-05 |
| 182 | LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 4 | 31 | 1.761e-06 | 4.502e-05 |
| 183 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 6 | 129 | 1.775e-06 | 4.514e-05 |
| 184 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 9 | 404 | 1.956e-06 | 4.945e-05 |
| 185 | MYD88 DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 4 | 32 | 2.008e-06 | 4.997e-05 |
| 186 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 4 | 32 | 2.008e-06 | 4.997e-05 |
| 187 | NEGATIVE REGULATION OF SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 4 | 32 | 2.008e-06 | 4.997e-05 |
| 188 | GLYCEROLIPID BIOSYNTHETIC PROCESS | 7 | 211 | 2.226e-06 | 5.509e-05 |
| 189 | CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 4 | 33 | 2.281e-06 | 5.615e-05 |
| 190 | REGULATION OF RESPONSE TO WOUNDING | 9 | 413 | 2.343e-06 | 5.737e-05 |
| 191 | RESPONSE TO ALKALOID | 6 | 137 | 2.521e-06 | 6.109e-05 |
| 192 | ACTIVATION OF MAPK ACTIVITY | 6 | 137 | 2.521e-06 | 6.109e-05 |
| 193 | T CELL HOMEOSTASIS | 4 | 34 | 2.579e-06 | 6.154e-05 |
| 194 | PROTEIN KINASE B SIGNALING | 4 | 34 | 2.579e-06 | 6.154e-05 |
| 195 | RENAL WATER HOMEOSTASIS | 4 | 34 | 2.579e-06 | 6.154e-05 |
| 196 | CELLULAR HOMEOSTASIS | 11 | 676 | 2.715e-06 | 6.445e-05 |
| 197 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 12 | 829 | 3.009e-06 | 7.107e-05 |
| 198 | RESPONSE TO ACID CHEMICAL | 8 | 319 | 3.214e-06 | 7.553e-05 |
| 199 | RESPONSE TO DRUG | 9 | 431 | 3.319e-06 | 7.761e-05 |
| 200 | REGULATION OF NECROPTOTIC PROCESS | 3 | 11 | 3.563e-06 | 8.29e-05 |
| 201 | CELLULAR RESPONSE TO GLUCAGON STIMULUS | 4 | 38 | 4.071e-06 | 9.423e-05 |
| 202 | CELLULAR CHEMICAL HOMEOSTASIS | 10 | 570 | 4.226e-06 | 9.735e-05 |
| 203 | PHOSPHOLIPID BIOSYNTHETIC PROCESS | 7 | 235 | 4.536e-06 | 0.000104 |
| 204 | REGULATION OF VITAMIN METABOLIC PROCESS | 3 | 12 | 4.741e-06 | 0.0001076 |
| 205 | POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 3 | 12 | 4.741e-06 | 0.0001076 |
| 206 | IMMUNE SYSTEM DEVELOPMENT | 10 | 582 | 5.08e-06 | 0.0001147 |
| 207 | LYMPHOCYTE ACTIVATION | 8 | 342 | 5.366e-06 | 0.0001206 |
| 208 | SINGLE ORGANISM CELL ADHESION | 9 | 459 | 5.53e-06 | 0.0001237 |
| 209 | REGULATION OF CATABOLIC PROCESS | 11 | 731 | 5.736e-06 | 0.0001277 |
| 210 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 9 | 465 | 6.141e-06 | 0.0001361 |
| 211 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 17 | 1805 | 6.801e-06 | 0.00015 |
| 212 | CELLULAR RESPONSE TO BIOTIC STIMULUS | 6 | 163 | 6.877e-06 | 0.0001509 |
| 213 | TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY | 3 | 14 | 7.813e-06 | 0.0001699 |
| 214 | REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 14 | 7.813e-06 | 0.0001699 |
| 215 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 7 | 258 | 8.359e-06 | 0.0001809 |
| 216 | REGULATION OF CELL ACTIVATION | 9 | 484 | 8.474e-06 | 0.0001825 |
| 217 | LEUKOCYTE MIGRATION | 7 | 259 | 8.572e-06 | 0.0001838 |
| 218 | GLUCOSE HOMEOSTASIS | 6 | 170 | 8.75e-06 | 0.0001859 |
| 219 | CARBOHYDRATE HOMEOSTASIS | 6 | 170 | 8.75e-06 | 0.0001859 |
| 220 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 8 | 370 | 9.531e-06 | 0.0002016 |
| 221 | REGULATION OF GLUCOSE TRANSPORT | 5 | 100 | 9.626e-06 | 0.0002027 |
| 222 | APOPTOTIC DNA FRAGMENTATION | 3 | 15 | 9.747e-06 | 0.0002034 |
| 223 | T CELL APOPTOTIC PROCESS | 3 | 15 | 9.747e-06 | 0.0002034 |
| 224 | RESPONSE TO GLUCAGON | 4 | 48 | 1.051e-05 | 0.0002182 |
| 225 | RESPONSE TO CORTICOSTEROID | 6 | 176 | 1.067e-05 | 0.0002206 |
| 226 | REGULATION OF CELL CELL ADHESION | 8 | 380 | 1.156e-05 | 0.0002381 |
| 227 | REGULATION OF BODY FLUID LEVELS | 9 | 506 | 1.209e-05 | 0.0002478 |
| 228 | LYMPHOCYTE HOMEOSTASIS | 4 | 50 | 1.238e-05 | 0.0002527 |
| 229 | REGULATION OF PROTEIN IMPORT | 6 | 183 | 1.332e-05 | 0.0002706 |
| 230 | REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 3 | 17 | 1.451e-05 | 0.0002922 |
| 231 | REGULATION OF LIPID CATABOLIC PROCESS | 4 | 52 | 1.449e-05 | 0.0002922 |
| 232 | PROTEIN DEPHOSPHORYLATION | 6 | 190 | 1.648e-05 | 0.0003305 |
| 233 | INOSITOL PHOSPHATE MEDIATED SIGNALING | 3 | 18 | 1.737e-05 | 0.0003455 |
| 234 | LYMPHOCYTE APOPTOTIC PROCESS | 3 | 18 | 1.737e-05 | 0.0003455 |
| 235 | REGULATION OF NEURON APOPTOTIC PROCESS | 6 | 192 | 1.749e-05 | 0.0003462 |
| 236 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 14 | 1360 | 2.039e-05 | 0.0004019 |
| 237 | DNA CATABOLIC PROCESS ENDONUCLEOLYTIC | 3 | 19 | 2.059e-05 | 0.0004042 |
| 238 | GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 7 | 297 | 2.078e-05 | 0.0004045 |
| 239 | REGULATION OF ORGANELLE ORGANIZATION | 13 | 1178 | 2.072e-05 | 0.0004045 |
| 240 | LEUKOCYTE ACTIVATION | 8 | 414 | 2.144e-05 | 0.0004156 |
| 241 | MULTICELLULAR ORGANISMAL WATER HOMEOSTASIS | 4 | 58 | 2.243e-05 | 0.000433 |
| 242 | NEGATIVE REGULATION OF CELL COMMUNICATION | 13 | 1192 | 2.347e-05 | 0.0004513 |
| 243 | REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 4 | 59 | 2.401e-05 | 0.000457 |
| 244 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 9 | 552 | 2.406e-05 | 0.000457 |
| 245 | NEGATIVE REGULATION OF CATABOLIC PROCESS | 6 | 203 | 2.395e-05 | 0.000457 |
| 246 | REGULATION OF GLUCOSE IMPORT | 4 | 60 | 2.567e-05 | 0.0004801 |
| 247 | REGULATION OF HOMOTYPIC CELL CELL ADHESION | 7 | 307 | 2.569e-05 | 0.0004801 |
| 248 | REGULATION OF PROTEIN TARGETING | 7 | 307 | 2.569e-05 | 0.0004801 |
| 249 | LEUKOCYTE HOMEOSTASIS | 4 | 60 | 2.567e-05 | 0.0004801 |
| 250 | NEGATIVE REGULATION OF LIPID CATABOLIC PROCESS | 3 | 21 | 2.815e-05 | 0.0005209 |
| 251 | LYMPHOCYTE DIFFERENTIATION | 6 | 209 | 2.821e-05 | 0.0005209 |
| 252 | RESPONSE TO NITRIC OXIDE | 3 | 21 | 2.815e-05 | 0.0005209 |
| 253 | LIPID MODIFICATION | 6 | 210 | 2.898e-05 | 0.000533 |
| 254 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 6 | 218 | 3.573e-05 | 0.0006546 |
| 255 | POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 3 | 23 | 3.733e-05 | 0.0006785 |
| 256 | LEUKOCYTE APOPTOTIC PROCESS | 3 | 23 | 3.733e-05 | 0.0006785 |
| 257 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 6 | 220 | 3.761e-05 | 0.0006808 |
| 258 | REGULATION OF EXECUTION PHASE OF APOPTOSIS | 3 | 24 | 4.257e-05 | 0.0007678 |
| 259 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 12 | 1087 | 4.555e-05 | 0.0008183 |
| 260 | WATER HOMEOSTASIS | 4 | 70 | 4.725e-05 | 0.0008456 |
| 261 | CELLULAR EXTRAVASATION | 3 | 25 | 4.828e-05 | 0.0008575 |
| 262 | APOPTOTIC NUCLEAR CHANGES | 3 | 25 | 4.828e-05 | 0.0008575 |
| 263 | CELL CELL ADHESION | 9 | 608 | 5.11e-05 | 0.0009041 |
| 264 | REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 11 | 926 | 5.153e-05 | 0.0009082 |
| 265 | RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 6 | 233 | 5.178e-05 | 0.0009092 |
| 266 | PLATELET ACTIVATION | 5 | 142 | 5.231e-05 | 0.0009151 |
| 267 | POSITIVE REGULATION OF TRANSPORT | 11 | 936 | 5.678e-05 | 0.0009895 |
| 268 | REGULATION OF INTRACELLULAR TRANSPORT | 9 | 621 | 6.016e-05 | 0.001045 |
| 269 | RESPONSE TO TOXIC SUBSTANCE | 6 | 241 | 6.244e-05 | 0.00108 |
| 270 | RESPONSE TO TEMPERATURE STIMULUS | 5 | 148 | 6.37e-05 | 0.001098 |
| 271 | REGULATION OF PROTEIN LOCALIZATION | 11 | 950 | 6.491e-05 | 0.001115 |
| 272 | POSITIVE REGULATION OF CELL CELL ADHESION | 6 | 243 | 6.537e-05 | 0.001118 |
| 273 | GLYCEROLIPID METABOLIC PROCESS | 7 | 356 | 6.567e-05 | 0.001119 |
| 274 | POSITIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE | 3 | 28 | 6.835e-05 | 0.001161 |
| 275 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 11 | 957 | 6.934e-05 | 0.001173 |
| 276 | REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 5 | 152 | 7.228e-05 | 0.001219 |
| 277 | PHOSPHOLIPID METABOLIC PROCESS | 7 | 364 | 7.549e-05 | 0.001264 |
| 278 | REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 3 | 29 | 7.609e-05 | 0.001264 |
| 279 | POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 3 | 29 | 7.609e-05 | 0.001264 |
| 280 | MUSCLE ADAPTATION | 3 | 29 | 7.609e-05 | 0.001264 |
| 281 | NEGATIVE REGULATION OF KINASE ACTIVITY | 6 | 250 | 7.647e-05 | 0.001266 |
| 282 | NEGATIVE REGULATION OF LIPID METABOLIC PROCESS | 4 | 80 | 7.98e-05 | 0.001312 |
| 283 | INSULIN RECEPTOR SIGNALING PATHWAY | 4 | 80 | 7.98e-05 | 0.001312 |
| 284 | NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 7 | 372 | 8.648e-05 | 0.001417 |
| 285 | JNK CASCADE | 4 | 82 | 8.787e-05 | 0.00143 |
| 286 | REGULATION OF PROTEIN MATURATION | 4 | 82 | 8.787e-05 | 0.00143 |
| 287 | POSITIVE REGULATION OF INTERLEUKIN 2 PRODUCTION | 3 | 31 | 9.322e-05 | 0.001511 |
| 288 | CELLULAR COMPONENT DISASSEMBLY | 8 | 515 | 9.979e-05 | 0.001612 |
| 289 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 7 | 381 | 0.0001004 | 0.001616 |
| 290 | AGING | 6 | 264 | 0.0001032 | 0.001655 |
| 291 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 11 | 1004 | 0.0001064 | 0.001701 |
| 292 | NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 4 | 88 | 0.0001157 | 0.001831 |
| 293 | REGULATION OF TRANSPORT | 15 | 1804 | 0.0001154 | 0.001831 |
| 294 | POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 4 | 88 | 0.0001157 | 0.001831 |
| 295 | RESPONSE TO HEAT | 4 | 89 | 0.0001209 | 0.001906 |
| 296 | NEGATIVE REGULATION OF PROTEIN COMPLEX DISASSEMBLY | 5 | 170 | 0.0001225 | 0.001926 |
| 297 | CELLULAR RESPONSE TO ALKALOID | 3 | 34 | 0.0001233 | 0.001932 |
| 298 | NEGATIVE REGULATION OF NEURON DEATH | 5 | 171 | 0.000126 | 0.00196 |
| 299 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 9 | 684 | 0.0001257 | 0.00196 |
| 300 | STRIATED MUSCLE CELL DIFFERENTIATION | 5 | 173 | 0.000133 | 0.002063 |
| 301 | NEGATIVE REGULATION OF PROTEIN PROCESSING | 3 | 35 | 0.0001346 | 0.002074 |
| 302 | NEGATIVE REGULATION OF PROTEIN MATURATION | 3 | 35 | 0.0001346 | 0.002074 |
| 303 | POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 3 | 36 | 0.0001466 | 0.002251 |
| 304 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 6 | 282 | 0.0001479 | 0.002264 |
| 305 | REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS | 4 | 94 | 0.0001494 | 0.002279 |
| 306 | DEPHOSPHORYLATION | 6 | 286 | 0.0001597 | 0.002428 |
| 307 | WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 3 | 39 | 0.0001865 | 0.002827 |
| 308 | REGULATION OF IMMUNE EFFECTOR PROCESS | 7 | 424 | 0.0001941 | 0.002933 |
| 309 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 3 | 40 | 0.0002012 | 0.00302 |
| 310 | MYELOID CELL DIFFERENTIATION | 5 | 189 | 0.000201 | 0.00302 |
| 311 | MITOTIC SPINDLE ASSEMBLY | 3 | 41 | 0.0002167 | 0.003231 |
| 312 | MICROTUBULE CYTOSKELETON ORGANIZATION INVOLVED IN MITOSIS | 3 | 41 | 0.0002167 | 0.003231 |
| 313 | REGULATION OF INTERLEUKIN 6 PRODUCTION | 4 | 104 | 0.0002205 | 0.003278 |
| 314 | POSITIVE REGULATION OF GLUCOSE TRANSPORT | 3 | 42 | 0.0002328 | 0.00345 |
| 315 | INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 4 | 106 | 0.0002372 | 0.003504 |
| 316 | REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 3 | 43 | 0.0002498 | 0.003678 |
| 317 | POSITIVE REGULATION OF CELL ACTIVATION | 6 | 311 | 0.000251 | 0.003684 |
| 318 | RESPONSE TO HYDROGEN PEROXIDE | 4 | 109 | 0.000264 | 0.003863 |
| 319 | ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 7 | 450 | 0.0002789 | 0.004069 |
| 320 | REGULATION OF ALCOHOL BIOSYNTHETIC PROCESS | 3 | 45 | 0.0002861 | 0.00416 |
| 321 | CELLULAR RESPONSE TO LIPID | 7 | 457 | 0.0003062 | 0.004439 |
| 322 | REGULATION OF LYMPHOCYTE MEDIATED IMMUNITY | 4 | 114 | 0.0003133 | 0.004528 |
| 323 | POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 3 | 47 | 0.0003256 | 0.00469 |
| 324 | POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 3 | 48 | 0.0003466 | 0.004947 |
| 325 | REGULATION OF LIPID KINASE ACTIVITY | 3 | 48 | 0.0003466 | 0.004947 |
| 326 | REGULATION OF INTERLEUKIN 2 PRODUCTION | 3 | 48 | 0.0003466 | 0.004947 |
| 327 | INNATE IMMUNE RESPONSE | 8 | 619 | 0.0003491 | 0.004967 |
| 328 | REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 4 | 118 | 0.0003573 | 0.005069 |
| 329 | RESPONSE TO METAL ION | 6 | 333 | 0.0003617 | 0.005115 |
| 330 | REGULATION OF TOLL LIKE RECEPTOR SIGNALING PATHWAY | 3 | 49 | 0.0003684 | 0.005179 |
| 331 | REGULATION OF STEROID BIOSYNTHETIC PROCESS | 3 | 49 | 0.0003684 | 0.005179 |
| 332 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 14 | 1784 | 0.0003756 | 0.005264 |
| 333 | SYSTEM PROCESS | 14 | 1785 | 0.0003777 | 0.005278 |
| 334 | REGULATION OF PROTEIN COMPLEX DISASSEMBLY | 5 | 217 | 0.00038 | 0.005294 |
| 335 | RESPONSE TO GROWTH FACTOR | 7 | 475 | 0.0003865 | 0.005368 |
| 336 | REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 4 | 122 | 0.0004055 | 0.005616 |
| 337 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 10 | 983 | 0.0004131 | 0.005704 |
| 338 | REGULATION OF ADAPTIVE IMMUNE RESPONSE | 4 | 123 | 0.0004183 | 0.005724 |
| 339 | REGULATION OF CYTOPLASMIC TRANSPORT | 7 | 481 | 0.0004167 | 0.005724 |
| 340 | T CELL DIFFERENTIATION | 4 | 123 | 0.0004183 | 0.005724 |
| 341 | REGULATION OF FEVER GENERATION | 2 | 11 | 0.0004317 | 0.005874 |
| 342 | NEGATIVE REGULATION OF NECROTIC CELL DEATH | 2 | 11 | 0.0004317 | 0.005874 |
| 343 | REGULATION OF T CELL MEDIATED IMMUNITY | 3 | 52 | 0.0004393 | 0.005959 |
| 344 | IMMUNE EFFECTOR PROCESS | 7 | 486 | 0.0004433 | 0.005995 |
| 345 | REGULATION OF NITRIC OXIDE BIOSYNTHETIC PROCESS | 3 | 53 | 0.0004647 | 0.006249 |
| 346 | CELLULAR RESPONSE TO AMINO ACID STIMULUS | 3 | 53 | 0.0004647 | 0.006249 |
| 347 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 12 | 1395 | 0.0004735 | 0.006349 |
| 348 | NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 6 | 351 | 0.000478 | 0.006391 |
| 349 | REGULATION OF ENDOTHELIAL CELL DEVELOPMENT | 2 | 12 | 0.0005171 | 0.006817 |
| 350 | REGULATION OF CHEMOKINE BIOSYNTHETIC PROCESS | 2 | 12 | 0.0005171 | 0.006817 |
| 351 | REGULATION OF ESTABLISHMENT OF ENDOTHELIAL BARRIER | 2 | 12 | 0.0005171 | 0.006817 |
| 352 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 7 | 498 | 0.0005126 | 0.006817 |
| 353 | POSITIVE REGULATION OF INTERLEUKIN 2 BIOSYNTHETIC PROCESS | 2 | 12 | 0.0005171 | 0.006817 |
| 354 | B CELL ACTIVATION | 4 | 132 | 0.0005462 | 0.00718 |
| 355 | RESPONSE TO ALCOHOL | 6 | 362 | 0.0005623 | 0.00737 |
| 356 | MUSCLE CELL DIFFERENTIATION | 5 | 237 | 0.0005679 | 0.007422 |
| 357 | REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 3 | 57 | 0.0005758 | 0.007497 |
| 358 | CELL DEVELOPMENT | 12 | 1426 | 0.0005768 | 0.007497 |
| 359 | POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 4 | 135 | 0.0005944 | 0.007704 |
| 360 | POSITIVE REGULATION OF STEROID BIOSYNTHETIC PROCESS | 2 | 13 | 0.00061 | 0.007756 |
| 361 | CELL PROLIFERATION | 8 | 672 | 0.0006015 | 0.007756 |
| 362 | HEPATOCYTE APOPTOTIC PROCESS | 2 | 13 | 0.00061 | 0.007756 |
| 363 | POSITIVE REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS | 3 | 58 | 0.000606 | 0.007756 |
| 364 | RESPONSE TO COBALT ION | 2 | 13 | 0.00061 | 0.007756 |
| 365 | REGULATION OF PROTEIN POLYUBIQUITINATION | 2 | 13 | 0.00061 | 0.007756 |
| 366 | BIOLOGICAL ADHESION | 10 | 1032 | 0.0006049 | 0.007756 |
| 367 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 4 | 138 | 0.0006456 | 0.008185 |
| 368 | REGULATION OF MONOOXYGENASE ACTIVITY | 3 | 60 | 0.0006693 | 0.008463 |
| 369 | POSITIVE REGULATION OF CELL ADHESION | 6 | 376 | 0.0006859 | 0.008626 |
| 370 | RESPONSE TO VIRUS | 5 | 247 | 0.0006845 | 0.008626 |
| 371 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 3 | 61 | 0.0007025 | 0.008811 |
| 372 | REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 2 | 14 | 0.0007104 | 0.008838 |
| 373 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 8 | 689 | 0.0007084 | 0.008838 |
| 374 | T CELL MIGRATION | 2 | 14 | 0.0007104 | 0.008838 |
| 375 | COGNITION | 5 | 251 | 0.0007359 | 0.009129 |
| 376 | CELLULAR RESPONSE TO OXYGEN LEVELS | 4 | 143 | 0.0007377 | 0.009129 |
| 377 | SINGLE ORGANISM BEHAVIOR | 6 | 384 | 0.0007654 | 0.009447 |
| 378 | POSITIVE REGULATION OF JUN KINASE ACTIVITY | 3 | 63 | 0.000772 | 0.009503 |
| 379 | NUCLEIC ACID PHOSPHODIESTER BOND HYDROLYSIS | 5 | 254 | 0.0007762 | 0.00953 |
| 380 | CELLULAR RESPONSE TO INSULIN STIMULUS | 4 | 146 | 0.0007972 | 0.009762 |
| 381 | REGULATION OF HEAT GENERATION | 2 | 15 | 0.0008182 | 0.009767 |
| 382 | CELLULAR RESPONSE TO NITRIC OXIDE | 2 | 15 | 0.0008182 | 0.009767 |
| 383 | REGULATION OF PROTEIN SECRETION | 6 | 389 | 0.0008186 | 0.009767 |
| 384 | RESPIRATORY BURST | 2 | 15 | 0.0008182 | 0.009767 |
| 385 | NEGATIVE REGULATION OF INTERLEUKIN 12 PRODUCTION | 2 | 15 | 0.0008182 | 0.009767 |
| 386 | LIPID BIOSYNTHETIC PROCESS | 7 | 539 | 0.0008178 | 0.009767 |
| 387 | CHRONIC INFLAMMATORY RESPONSE | 2 | 15 | 0.0008182 | 0.009767 |
| 388 | POSITIVE REGULATION OF MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS | 2 | 15 | 0.0008182 | 0.009767 |
| 389 | REGULATION OF VIRAL INDUCED CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 2 | 15 | 0.0008182 | 0.009767 |
| 390 | NEUROTROPHIN TRK RECEPTOR SIGNALING PATHWAY | 2 | 15 | 0.0008182 | 0.009767 |
| 391 | PEPTIDYL SERINE MODIFICATION | 4 | 148 | 0.0008388 | 0.009906 |
| 392 | REGULATION OF CELLULAR LOCALIZATION | 11 | 1277 | 0.0008368 | 0.009906 |
| 393 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 7 | 541 | 0.0008357 | 0.009906 |
| 394 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 7 | 541 | 0.0008357 | 0.009906 |
| 395 | REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 3 | 65 | 0.0008458 | 0.009963 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | KINASE ACTIVITY | 18 | 842 | 9.522e-12 | 8.846e-09 |
| 2 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 18 | 992 | 1.403e-10 | 6.518e-08 |
| 3 | CYTOKINE RECEPTOR BINDING | 11 | 271 | 2.454e-10 | 7.599e-08 |
| 4 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 5 | 15 | 4.616e-10 | 1.072e-07 |
| 5 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 7 | 70 | 1.088e-09 | 2.022e-07 |
| 6 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 6 | 43 | 2.297e-09 | 3.556e-07 |
| 7 | TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY BINDING | 6 | 47 | 4.01e-09 | 5.322e-07 |
| 8 | PHOSPHATIDYLINOSITOL KINASE ACTIVITY | 6 | 51 | 6.668e-09 | 6.882e-07 |
| 9 | DEATH RECEPTOR ACTIVITY | 5 | 24 | 6.408e-09 | 6.882e-07 |
| 10 | PROTEASE BINDING | 7 | 104 | 1.79e-08 | 1.663e-06 |
| 11 | PROTEIN KINASE ACTIVITY | 13 | 640 | 2.192e-08 | 1.851e-06 |
| 12 | ENZYME BINDING | 20 | 1737 | 2.8e-08 | 2.168e-06 |
| 13 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 11 | 445 | 4.296e-08 | 3.07e-06 |
| 14 | KINASE REGULATOR ACTIVITY | 8 | 186 | 5.388e-08 | 3.576e-06 |
| 15 | PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY | 4 | 16 | 1.052e-07 | 6.269e-06 |
| 16 | ADENYL NUCLEOTIDE BINDING | 18 | 1514 | 1.08e-07 | 6.269e-06 |
| 17 | CYSTEINE TYPE ENDOPEPTIDASE REGULATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 5 | 42 | 1.233e-07 | 6.74e-06 |
| 18 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 6 | 86 | 1.612e-07 | 8.321e-06 |
| 19 | DEATH RECEPTOR BINDING | 4 | 18 | 1.761e-07 | 8.608e-06 |
| 20 | PROTEIN HETERODIMERIZATION ACTIVITY | 10 | 468 | 7.214e-07 | 3.351e-05 |
| 21 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 8 | 264 | 7.831e-07 | 3.464e-05 |
| 22 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 4 | 30 | 1.537e-06 | 6.491e-05 |
| 23 | RIBONUCLEOTIDE BINDING | 18 | 1860 | 2.249e-06 | 8.704e-05 |
| 24 | ENZYME REGULATOR ACTIVITY | 13 | 959 | 2.241e-06 | 8.704e-05 |
| 25 | INSULIN RECEPTOR SUBSTRATE BINDING | 3 | 11 | 3.563e-06 | 0.0001324 |
| 26 | MOLECULAR FUNCTION REGULATOR | 15 | 1353 | 3.888e-06 | 0.0001389 |
| 27 | IDENTICAL PROTEIN BINDING | 14 | 1209 | 5.348e-06 | 0.000184 |
| 28 | PROTEIN KINASE A CATALYTIC SUBUNIT BINDING | 3 | 15 | 9.747e-06 | 0.0003234 |
| 29 | INTERLEUKIN 1 RECEPTOR BINDING | 3 | 16 | 1.197e-05 | 0.0003835 |
| 30 | CYSTEINE TYPE PEPTIDASE ACTIVITY | 6 | 184 | 1.374e-05 | 0.0004254 |
| 31 | PROTEIN DIMERIZATION ACTIVITY | 13 | 1149 | 1.591e-05 | 0.0004769 |
| 32 | SIGNAL TRANSDUCER ACTIVITY | 16 | 1731 | 1.742e-05 | 0.0005057 |
| 33 | PROTEIN SERINE THREONINE PHOSPHATASE ACTIVITY | 4 | 64 | 3.316e-05 | 0.0009335 |
| 34 | CAMP BINDING | 3 | 23 | 3.733e-05 | 0.0009908 |
| 35 | CYSTEINE TYPE ENDOPEPTIDASE INHIBITOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 3 | 23 | 3.733e-05 | 0.0009908 |
| 36 | RECEPTOR BINDING | 14 | 1476 | 5.043e-05 | 0.001301 |
| 37 | TUMOR NECROSIS FACTOR RECEPTOR BINDING | 3 | 30 | 8.437e-05 | 0.002118 |
| 38 | ENZYME INHIBITOR ACTIVITY | 7 | 378 | 9.555e-05 | 0.002336 |
| 39 | KINASE INHIBITOR ACTIVITY | 4 | 89 | 0.0001209 | 0.002879 |
| 40 | CYCLIC NUCLEOTIDE BINDING | 3 | 36 | 0.0001466 | 0.003404 |
| 41 | PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 5 | 178 | 0.000152 | 0.003444 |
| 42 | PROTEIN KINASE A BINDING | 3 | 42 | 0.0002328 | 0.00515 |
| 43 | KINASE BINDING | 8 | 606 | 0.0003028 | 0.006542 |
| 44 | PEPTIDASE REGULATOR ACTIVITY | 5 | 214 | 0.0003566 | 0.007528 |
| 45 | PROTEIN PHOSPHATASE BINDING | 4 | 120 | 0.0003809 | 0.007863 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 13 | 237 | 1.008e-13 | 2.944e-11 |
| 2 | PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX | 7 | 20 | 7.852e-14 | 2.944e-11 |
| 3 | CATALYTIC COMPLEX | 20 | 1038 | 3.252e-12 | 6.331e-10 |
| 4 | MEMBRANE MICRODOMAIN | 12 | 288 | 2.512e-11 | 3.667e-09 |
| 5 | MEMBRANE PROTEIN COMPLEX | 17 | 1020 | 1.891e-09 | 2.209e-07 |
| 6 | TRANSFERASE COMPLEX | 14 | 703 | 7.332e-09 | 7.136e-07 |
| 7 | PROTEIN KINASE COMPLEX | 6 | 90 | 2.117e-07 | 1.766e-05 |
| 8 | CILIARY BASE | 4 | 23 | 5.041e-07 | 3.68e-05 |
| 9 | CD40 RECEPTOR COMPLEX | 3 | 11 | 3.563e-06 | 0.0002312 |
| 10 | EXTRINSIC COMPONENT OF MEMBRANE | 7 | 252 | 7.169e-06 | 0.0004187 |
| 11 | PHOSPHATASE COMPLEX | 4 | 48 | 1.051e-05 | 0.0005577 |
| 12 | MEMBRANE REGION | 13 | 1134 | 1.384e-05 | 0.0006216 |
| 13 | PLASMA MEMBRANE PROTEIN COMPLEX | 9 | 510 | 1.287e-05 | 0.0006216 |
| 14 | INTRINSIC COMPONENT OF PLASMA MEMBRANE | 15 | 1649 | 4.133e-05 | 0.001724 |
| 15 | PLASMA MEMBRANE RECEPTOR COMPLEX | 5 | 175 | 0.0001404 | 0.005465 |
Over-represented Pathway
| Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|---|
| 1 | hsa04210_Apoptosis | 57 | 89 | 4.715e-145 | 8.487e-143 | |
| 2 | hsa04380_Osteoclast_differentiation | 21 | 128 | 2.686e-32 | 2.417e-30 | |
| 3 | hsa04660_T_cell_receptor_signaling_pathway | 18 | 108 | 9.001e-28 | 4.111e-26 | |
| 4 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 19 | 136 | 9.136e-28 | 4.111e-26 | |
| 5 | hsa04662_B_cell_receptor_signaling_pathway | 16 | 75 | 1.418e-26 | 5.107e-25 | |
| 6 | hsa04010_MAPK_signaling_pathway | 21 | 268 | 2.935e-25 | 8.805e-24 | |
| 7 | hsa04620_Toll.like_receptor_signaling_pathway | 16 | 102 | 2.986e-24 | 7.679e-23 | |
| 8 | hsa04722_Neurotrophin_signaling_pathway | 16 | 127 | 1.225e-22 | 2.756e-21 | |
| 9 | hsa04370_VEGF_signaling_pathway | 13 | 76 | 2.508e-20 | 5.016e-19 | |
| 10 | hsa04910_Insulin_signaling_pathway | 14 | 138 | 1.688e-18 | 3.038e-17 | |
| 11 | hsa04062_Chemokine_signaling_pathway | 14 | 189 | 1.502e-16 | 2.458e-15 | |
| 12 | hsa04510_Focal_adhesion | 14 | 200 | 3.334e-16 | 5.002e-15 | |
| 13 | hsa04914_Progesterone.mediated_oocyte_maturation | 11 | 87 | 8.6e-16 | 1.191e-14 | |
| 14 | hsa04973_Carbohydrate_digestion_and_absorption | 9 | 44 | 4.198e-15 | 5.398e-14 | |
| 15 | hsa04664_Fc_epsilon_RI_signaling_pathway | 10 | 79 | 1.906e-14 | 2.287e-13 | |
| 16 | hsa04150_mTOR_signaling_pathway | 9 | 52 | 2.141e-14 | 2.409e-13 | |
| 17 | hsa04151_PI3K_AKT_signaling_pathway | 15 | 351 | 3.878e-14 | 4.106e-13 | |
| 18 | hsa04014_Ras_signaling_pathway | 13 | 236 | 9.548e-14 | 9.548e-13 | |
| 19 | hsa04012_ErbB_signaling_pathway | 9 | 87 | 2.767e-12 | 2.622e-11 | |
| 20 | hsa04621_NOD.like_receptor_signaling_pathway | 8 | 59 | 5.171e-12 | 4.653e-11 | |
| 21 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 9 | 95 | 6.23e-12 | 5.34e-11 | |
| 22 | hsa04630_Jak.STAT_signaling_pathway | 10 | 155 | 1.843e-11 | 1.508e-10 | |
| 23 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 7 | 42 | 2.604e-11 | 2.038e-10 | |
| 24 | hsa04920_Adipocytokine_signaling_pathway | 7 | 68 | 8.839e-10 | 6.629e-09 | |
| 25 | hsa04070_Phosphatidylinositol_signaling_system | 7 | 78 | 2.356e-09 | 1.697e-08 | |
| 26 | hsa04670_Leukocyte_transendothelial_migration | 7 | 117 | 4.061e-08 | 2.812e-07 | |
| 27 | hsa04720_Long.term_potentiation | 6 | 70 | 4.657e-08 | 3.104e-07 | |
| 28 | hsa04622_RIG.I.like_receptor_signaling_pathway | 6 | 71 | 5.075e-08 | 3.263e-07 | |
| 29 | hsa04114_Oocyte_meiosis | 6 | 114 | 8.602e-07 | 5.339e-06 | |
| 30 | hsa04115_p53_signaling_pathway | 5 | 69 | 1.537e-06 | 9.221e-06 | |
| 31 | hsa04810_Regulation_of_actin_cytoskeleton | 7 | 214 | 2.445e-06 | 1.419e-05 | |
| 32 | hsa04310_Wnt_signaling_pathway | 6 | 151 | 4.429e-06 | 2.491e-05 | |
| 33 | hsa04020_Calcium_signaling_pathway | 6 | 177 | 1.102e-05 | 6.009e-05 | |
| 34 | hsa04623_Cytosolic_DNA.sensing_pathway | 4 | 56 | 1.95e-05 | 0.0001032 | |
| 35 | hsa00562_Inositol_phosphate_metabolism | 4 | 57 | 2.092e-05 | 0.0001076 | |
| 36 | hsa04640_Hematopoietic_cell_lineage | 4 | 88 | 0.0001157 | 0.0005784 | |
| 37 | hsa04360_Axon_guidance | 4 | 130 | 0.0005157 | 0.002509 | |
| 38 | hsa04962_Vasopressin.regulated_water_reabsorption | 2 | 44 | 0.006992 | 0.03312 | |
| 39 | hsa04120_Ubiquitin_mediated_proteolysis | 3 | 139 | 0.00731 | 0.03374 | |
| 40 | hsa04742_Taste_transduction | 2 | 52 | 0.009658 | 0.04346 | |
| 41 | hsa04340_Hedgehog_signaling_pathway | 2 | 56 | 0.01114 | 0.04889 | |
| 42 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 3 | 168 | 0.01223 | 0.0524 | |
| 43 | hsa04976_Bile_secretion | 2 | 71 | 0.01749 | 0.0732 | |
| 44 | hsa04971_Gastric_acid_secretion | 2 | 74 | 0.0189 | 0.07734 | |
| 45 | hsa04970_Salivary_secretion | 2 | 89 | 0.02668 | 0.1066 | |
| 46 | hsa04540_Gap_junction | 2 | 90 | 0.02723 | 0.1066 | |
| 47 | hsa04912_GnRH_signaling_pathway | 2 | 101 | 0.03366 | 0.1262 | |
| 48 | hsa04916_Melanogenesis | 2 | 101 | 0.03366 | 0.1262 | |
| 49 | hsa04270_Vascular_smooth_muscle_contraction | 2 | 116 | 0.04328 | 0.159 | |
| 50 | hsa04530_Tight_junction | 2 | 133 | 0.05525 | 0.1989 | |
| 51 | hsa04740_Olfactory_transduction | 2 | 388 | 0.3035 | 1 |
lncRNA-mediated sponge
| Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TBX5-AS1 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-450b-5p;hsa-miR-590-5p;hsa-miR-629-3p | 20 | PIK3R1 | Sponge network | -2.108 | 0 | -1.285 | 0 | 0.544 |
| 2 | AC109642.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-424-5p;hsa-miR-590-3p;hsa-miR-93-5p;hsa-miR-96-5p | 19 | PIK3R1 | Sponge network | -2.791 | 0 | -1.285 | 0 | 0.529 |
| 3 | RP11-389C8.2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-335-3p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 16 | PIK3R1 | Sponge network | -2.039 | 0 | -1.285 | 0 | 0.52 |
| 4 | LINC00968 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 21 | PIK3R1 | Sponge network | -4.19 | 0 | -1.285 | 0 | 0.51 |
| 5 | RP11-720L2.4 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-93-5p | 13 | PIK3R1 | Sponge network | -2.305 | 0 | -1.285 | 0 | 0.496 |
| 6 | LINC00702 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-450b-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 23 | PIK3R1 | Sponge network | -2.856 | 0 | -1.285 | 0 | 0.494 |
| 7 | MAGI2-AS3 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 18 | PIK3R1 | Sponge network | -1.892 | 0 | -1.285 | 0 | 0.486 |
| 8 | LINC00472 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-93-5p | 14 | PIK3R1 | Sponge network | -2.952 | 0 | -1.285 | 0 | 0.458 |
| 9 | FENDRR | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 17 | PIK3R1 | Sponge network | -4.222 | 0 | -1.285 | 0 | 0.438 |
| 10 | AC007743.1 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-424-5p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p | 12 | PIK3R1 | Sponge network | -2.595 | 0 | -1.285 | 0 | 0.436 |
| 11 | RP11-1024P17.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-629-3p | 15 | PIK3R1 | Sponge network | -2.062 | 0 | -1.285 | 0 | 0.418 |
| 12 | RP11-456K23.1 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p | 23 | PIK3R1 | Sponge network | -1.488 | 0 | -1.285 | 0 | 0.416 |
| 13 | RP11-354E11.2 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-96-5p | 17 | PIK3R1 | Sponge network | -2.138 | 0 | -1.285 | 0 | 0.41 |
| 14 | RP11-401P9.4 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-590-5p;hsa-miR-93-5p | 14 | PIK3R1 | Sponge network | -3.04 | 0 | -1.285 | 0 | 0.408 |
| 15 | CTD-2013N24.2 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 18 | PIK3R1 | Sponge network | -1.745 | 0 | -1.285 | 0 | 0.407 |
| 16 | RP11-532F6.3 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | -2.028 | 0 | -1.285 | 0 | 0.395 |
| 17 | MIR497HG |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 19 | PIK3R1 | Sponge network | -2.142 | 0 | -1.285 | 0 | 0.391 |
| 18 | RP11-456K23.1 |
hsa-miR-106b-5p;hsa-miR-146b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-29b-3p;hsa-miR-362-5p;hsa-miR-542-3p;hsa-miR-93-5p | 10 | AKT3 | Sponge network | -1.488 | 0 | -1.44 | 0 | 0.389 |
| 19 | RP11-399O19.9 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-93-5p | 10 | PIK3R1 | Sponge network | -0.873 | 0.00072 | -1.285 | 0 | 0.38 |
| 20 | FGF14-AS2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-96-5p | 12 | PIK3R1 | Sponge network | -2.159 | 0 | -1.285 | 0 | 0.378 |
| 21 | HHIP-AS1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-424-5p;hsa-miR-590-3p | 12 | PIK3R1 | Sponge network | -2.807 | 0 | -1.285 | 0 | 0.374 |
| 22 | LINC00092 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-424-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-629-3p | 13 | PIK3R1 | Sponge network | -2.383 | 0 | -1.285 | 0 | 0.369 |
| 23 | RP11-378A13.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 15 | PIK3R1 | Sponge network | -1.713 | 0 | -1.285 | 0 | 0.367 |
| 24 | SH3RF3-AS1 | hsa-miR-128-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-590-5p | 12 | PIK3R1 | Sponge network | -1.583 | 0 | -1.285 | 0 | 0.364 |
| 25 | AC011899.9 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-590-3p | 12 | PIK3R1 | Sponge network | -2.611 | 0 | -1.285 | 0 | 0.364 |
| 26 | AC079630.4 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-424-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-93-5p | 12 | PIK3R1 | Sponge network | -3.758 | 0 | -1.285 | 0 | 0.359 |
| 27 | RP5-1042I8.7 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 12 | PIK3R1 | Sponge network | -0.733 | 0.00018 | -1.285 | 0 | 0.358 |
| 28 | AC003090.1 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 14 | PIK3R1 | Sponge network | -3.16 | 2.0E-5 | -1.285 | 0 | 0.358 |
| 29 | GAS6-AS2 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-335-3p;hsa-miR-590-5p | 15 | PIK3R1 | Sponge network | -1.761 | 0 | -1.285 | 0 | 0.354 |
| 30 | LINC00961 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-424-5p;hsa-miR-589-3p;hsa-miR-96-5p | 12 | PIK3R1 | Sponge network | -2.724 | 0 | -1.285 | 0 | 0.346 |
| 31 | AC011526.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-93-5p;hsa-miR-96-5p | 10 | PIK3R1 | Sponge network | -2.783 | 0 | -1.285 | 0 | 0.338 |
| 32 | AC004947.2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-450b-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p | 15 | PIK3R1 | Sponge network | -3.94 | 0 | -1.285 | 0 | 0.332 |
| 33 | WDFY3-AS2 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-96-5p | 17 | PIK3R1 | Sponge network | -1.297 | 0 | -1.285 | 0 | 0.329 |
| 34 | RP11-354E11.2 |
hsa-miR-130b-3p;hsa-miR-193a-3p;hsa-miR-193b-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-26b-3p;hsa-miR-301a-3p;hsa-miR-330-5p;hsa-miR-590-3p | 10 | ENDOD1 | Sponge network | -2.138 | 0 | 0.057 | 0.80229 | 0.32 |
| 35 | NR2F1-AS1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 17 | PIK3R1 | Sponge network | -0.427 | 0.1559 | -1.285 | 0 | 0.318 |
| 36 | LINC00607 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-582-5p;hsa-miR-590-5p;hsa-miR-629-3p | 10 | PIK3R1 | Sponge network | -2.277 | 0 | -1.285 | 0 | 0.316 |
| 37 | RP11-462G12.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-582-5p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -1.071 | 0.01175 | -1.285 | 0 | 0.302 |
| 38 | AC016735.2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-21-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-96-5p | 10 | PIK3R1 | Sponge network | -2.711 | 0.00282 | -1.285 | 0 | 0.298 |
| 39 | RP11-88I21.2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 11 | PIK3R1 | Sponge network | -8.789 | 0 | -1.285 | 0 | 0.297 |
| 40 | RP11-1008C21.2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-629-3p;hsa-miR-93-5p | 13 | PIK3R1 | Sponge network | -1.249 | 0 | -1.285 | 0 | 0.297 |
| 41 | RP11-365O16.3 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -2.765 | 0.00017 | -1.285 | 0 | 0.293 |
| 42 | CASC2 | hsa-miR-106a-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p | 13 | PIK3R1 | Sponge network | -1.086 | 0 | -1.285 | 0 | 0.29 |
| 43 | RP11-284N8.3 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 11 | PIK3R1 | Sponge network | -0.761 | 0.05061 | -1.285 | 0 | 0.285 |
| 44 | AF131215.9 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-21-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-590-3p | 10 | PIK3R1 | Sponge network | -1.808 | 0 | -1.285 | 0 | 0.282 |
| 45 | RP11-352D13.6 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-424-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 13 | PIK3R1 | Sponge network | -4.634 | 0 | -1.285 | 0 | 0.28 |
| 46 | LIPE-AS1 | hsa-miR-106a-5p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-590-5p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -0.734 | 0.00039 | -1.285 | 0 | 0.28 |
| 47 | RP11-476D10.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-590-3p;hsa-miR-96-5p | 10 | PIK3R1 | Sponge network | -4.519 | 0 | -1.285 | 0 | 0.279 |
| 48 | BDNF-AS | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 10 | PIK3R1 | Sponge network | -0.568 | 0.02011 | -1.285 | 0 | 0.277 |
| 49 | LINC00443 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p | 10 | PIK3R1 | Sponge network | -3.704 | 0.0003 | -1.285 | 0 | 0.276 |
| 50 | RP11-1008C21.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-629-3p | 12 | PIK3R1 | Sponge network | -1.826 | 3.0E-5 | -1.285 | 0 | 0.272 |
| 51 | SNHG18 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -1.073 | 0.00533 | -1.285 | 0 | 0.27 |
| 52 | C1orf132 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-182-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 10 | PIK3R1 | Sponge network | -0.86 | 0.02429 | -1.285 | 0 | 0.269 |
| 53 | TBX5-AS1 |
hsa-miR-141-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-3200-3p;hsa-miR-324-5p;hsa-miR-335-3p;hsa-miR-33a-5p;hsa-miR-450b-5p;hsa-miR-590-5p | 10 | IRAK3 | Sponge network | -2.108 | 0 | -1.317 | 1.0E-5 | 0.267 |
| 54 | RP1-78O14.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-335-3p;hsa-miR-629-3p | 10 | PIK3R1 | Sponge network | -4.409 | 0 | -1.285 | 0 | 0.264 |
| 55 | RP5-839B4.8 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-335-3p;hsa-miR-629-3p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -5.037 | 0 | -1.285 | 0 | 0.262 |
| 56 | DIO3OS | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-21-5p;hsa-miR-424-5p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | -1.936 | 0.00085 | -1.285 | 0 | 0.262 |
| 57 | LINC00261 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p | 16 | PIK3R1 | Sponge network | -2.566 | 0.00025 | -1.285 | 0 | 0.259 |
| 58 | LINC00619 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p | 10 | PIK3R1 | Sponge network | -2.307 | 0.02217 | -1.285 | 0 | 0.255 |
| 59 | DNM3OS | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-590-5p;hsa-miR-93-5p | 13 | PIK3R1 | Sponge network | 0.053 | 0.85755 | -1.285 | 0 | 0.255 |
| 60 | CTA-221G9.11 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 12 | PIK3R1 | Sponge network | -0.645 | 0.06404 | -1.285 | 0 | 0.254 |
| 61 | PCED1B-AS1 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-335-3p;hsa-miR-93-5p;hsa-miR-96-5p | 11 | PIK3R1 | Sponge network | -0.672 | 0.02084 | -1.285 | 0 | 0.254 |